Omnicare (OCR) 10-Q 24 Oct 14 2014 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information Document	9 Months Ended
	Sep. 30, 2014
Document Information [Line Items]	'
Entity Registrant Name	'OMNICARE INC
Entity Central Index Key	'0000353230
Current Fiscal Year End Date	'--12-31
Entity Filer Category	'Large Accelerated Filer
Document Type	'10-Q
Document Period End Date	30-Sep-14
Document Fiscal Year Focus	'2014
Document Fiscal Period Focus	'Q3
Amendment Flag	'false
Entity Common Stock, Shares Outstanding	97,883,851

CONSOLIDATED_STATEMENTS_OF_INC

CONSOLIDATED STATEMENTS OF INCOME UNAUDITED (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Income Statement [Abstract]	'	'	'	'
Revenue, Net	$1,608,055	$1,515,168	$4,789,677	$4,477,229
Cost of sales	1,256,595	1,163,197	3,725,533	3,416,039
Gross profit	351,460	351,971	1,064,144	1,061,190
Selling, general and administrative expenses	178,940	182,668	549,816	565,276
Provision for doubtful accounts	19,911	24,963	62,562	75,113
Settlement, litigation and other related charges	12,868	143,484	27,467	169,615
Other charges	3,999	61,632	25,559	96,906
Operating income	135,742	-60,776	398,740	154,280
Interest expense, net of investment income	-28,717	-34,925	-88,138	-94,011
Income before income taxes	107,025	-95,701	310,602	60,269
Income tax (benefit) expense	38,948	-26,350	117,641	34,004
Income from continuing operations	68,077	-69,351	192,961	26,265
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest	-3,246	3,042	-42,385	13,999
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	64,831	-66,309	150,576	40,264
Earnings (loss) per common share - Basic:	'	'	'	'
Income (Loss) from Continuing Operations, Per Basic Share	$0.70	($0.68)	$1.98	$0.26
Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share	($0.03)	$0.03	($0.43)	$0.14
Net income	$0.67	($0.65)	$1.54	$0.39
Earnings (loss) per common share - Diluted:	'	'	'	'
Income (Loss) from Continuing Operations, Per Diluted Share	$0.65	($0.68)	$1.81	$0.24
Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share	($0.03)	$0.03	($0.40)	$0.13
Diluted earnings per share	$0.61	($0.65)	$1.42	$0.37
Dividends per common share	$0.20	$0.14	$0.60	$0.42
Weighted average number of common shares outstanding:	'	'	'	'
Weighted Average Number of Shares Outstanding, Basic	97,019	101,811	97,521	102,624
Diluted shares	105,548	101,811	106,450	109,612
Comprehensive income (loss)	$65,170	($66,305)	$151,182	$40,170

CONSOLIDATED_BALANCE_SHEETS_UN

CONSOLIDATED BALANCE SHEETS UNAUDITED (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$286,943	$356,001
Accounts receivable, less allowances of $194,680 (2013 - 202,602)	651,224	695,684
Inventories	494,563	512,418
Deferred income tax benefits	56,084	135,094
Other current assets	315,165	265,536
Current assets of discontinued operations	0	49,995
Total current assets	1,803,979	2,014,728
Properties and equipment, at cost less accumulated depreciation of $295,490 (2013-$263,603)	330,601	305,888
Goodwill	4,060,683	4,057,456
Identifiable intangible assets, less accumulated amortization of $250,518 (2013-$227,657)	106,425	129,974
Other noncurrent assets	95,649	96,722
Non current assets of discontinued operations	0	87,078
Total noncurrent assets	4,593,358	4,677,118
Total assets	6,397,337	6,691,846
Current liabilities:	'	'
Accounts payable	220,288	181,022
Accrued employee compensation	56,394	50,240
Debt, Current	495,713	527,204
Other current liabilities	166,324	355,845
Current liabilities of discontinued operations	0	18,846
Total current liabilities	938,719	1,133,157
Long-term debt, net	1,411,470	1,418,819
Deferred income tax liabilities	1,022,857	1,012,733
Other noncurrent liabilities	60,701	53,835
Liabilities of Disposal Group, Including Discontinued Operation, Noncurrent	0	1,398
Total noncurrent liabilities	2,495,028	2,486,785
Total liabilities	3,433,747	3,619,942
Convertible Debt (Note 5)	308,787	331,101
Stockholders' equity:	'	'
Preferred stock, no par value, 1,000,000 shares authorized, none issued and outstanding	0	0
Common stock, $1 par value, 200,000,000 shares authorized, 135,487,957 shares issued (2013-134,623,736 shares issued)	135,488	134,624
Paid in capital	2,083,162	2,047,195
Retained earnings	1,785,475	1,693,799
Treasury stock, at cost- 37,604,106 shares (2013-34,013,923 shares )	-1,347,387	-1,132,274
Accumulated Other Comprehensive Income (Loss), Net of Tax	-1,935	-2,541
Total stockholders' equity	2,654,803	2,740,803
Total liabilities and stockholders' equity	$6,397,337	$6,691,846

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS UNAUDITED (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Cash flows from operating activities:	'	'
Net income (loss)	$150,576	$40,264
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest	42,385	-13,999
Adjustments to reconcile net income to net cash flows from operating activities:	'	'
Depreciation expense	43,010	41,643
Amortization expense	57,419	57,884
Gains (Losses) on Extinguishment of Debt	8,419	55,652
Gain (Loss) on Disposition of Business	805	36,062
Gale settlement payment, net	-120,000	0
Changes in assets and liabilities, net of effects from acquisition and divestiture of businesses:	'	'
Accounts receivable, net of provision for doubtful accounts	15,848	70,107
Inventories	17,807	-37,573
Other current and noncurrent assets	-20,853	5,897
Accounts payable	58,399	22,717
Accrued employee compensation	6,389	-17,196
Current and noncurrent liabilities	94,350	194,528
Net cash flows from operating activities of continuing operations	354,554	455,986
Net cash flows from operating activities of discontinued operations	863	-1,321
Net cash flows from operating activities	355,417	454,665
Cash flows from investing activities:	'	'
Acquisition of businesses, net of cash received	0	3,798
Proceeds from Divestiture of Businesses	71,194	11,083
Capital expenditures	-67,871	-73,279
Payments for (Proceeds from) Other Investing Activities	18	-441
Net cash flows used in investing activities of continuing operations	3,305	-65,553
Net cash flows used in investing activities of discontinued operations	-863	-848
Net cash flows used in investing activities	2,442	-66,401
Cash flows from financing activities:	'	'
Payments on Term Loans	-15,938	-15,938
Payments on long-term borrowings and obligations	-176,983	-190,403
Payments of Debt Issuance Costs	0	4,851
Increase (decrease) in cash overdraft balance	-19,786	-11,490
Payments for Omnicare common stock repurchases	-160,438	-91,259
Proceeds for stock awards and exercise of stock options, net of stock tendered in payment	-293	17,934
Dividends paid	-58,419	-43,011
Other	4,940	2,228
Net Cash Provided by (Used in) Financing Activities	-426,917	-336,790
Net increase (decrease) in cash and cash equivalents	-69,058	51,474
Increase (decrease) in cash and cash equivalents of discontinued operations	0	-2,169
Increase (decrease) in cash and cash equivalents of continuing operations	-69,058	53,643
Cash and cash equivalents at beginning of period	356,001	444,620
Cash and cash equivalents at end of period	$286,943	$498,263

CONSOLIDATED_BALANCE_SHEET_PAR

CONSOLIDATED BALANCE SHEET (PARENTHETICAL) UNAUDITED (Parentheticals) (USD $)	3 Months Ended	9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2014	Dec. 31, 2013
Parenthetical Balance Sheet [Abstract]	'	'	'
Allowance for Doubtful Accounts Receivable, Current	$194,680	$194,680	$202,602
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	295,490	295,490	263,603
Finite-Lived Intangible Assets, Accumulated Amortization	250,518	250,518	227,657
Preferred Stock, No Par Value	$0	$0	$0
Preferred Stock, Shares Authorized	1,000,000	1,000,000	1,000,000
Preferred Stock, Shares Issued	0	0	0
Preferred Stock, Shares Outstanding	0	0	0
Common Stock, Par or Stated Value Per Share	$1	$1	$1
Common Stock, Shares Authorized	200,000,000	200,000,000	200,000,000
Common Stock, Shares, Issued	135,487,957	135,487,957	134,623,736
Treasury Stock, Shares	37,604,106	37,604,106	34,013,923
Amortization of Financing Costs	$1,000	$3,000	'

Basis_of_Presentation

Basis of Presentation	9 Months Ended
	Sep. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Basis of Presentation	'
	Omnicare, Inc. and its consolidated subsidiaries (“Omnicare” or the “Company”) have prepared the accompanying unaudited Consolidated Financial Statements in accordance with the accounting policies described in its consolidated financial statements and the notes thereto included in the Company’s 2013 Annual Report on Form 10-K (“2013 Annual Report”), and the interim reporting requirements of Form 10-Q. Accordingly, certain information and disclosures normally included in the Company’s annual financial statements have been condensed or omitted. The Consolidated Financial Statements should be read in conjunction with the Company’s consolidated financial statements and related notes included in the 2013 Annual Report, together with any related updates included in the Company’s subsequent periodic Securities and Exchange Commission (“SEC”) filings. In 2013, the Company’s end-of-life hospice pharmacy business (“Hospice”) as well as certain retail operations (“Retail”) qualified for discontinued operations treatment. The Company’s results of operations for all periods presented reflect the results of these businesses, including related expenses, as discontinued operations. See “Note 3 - Discontinued Operations”. Certain prior year amounts, primarily related to discontinued operations, have been reclassified to conform to the current year presentation.

Significant_Accounting_Policie

Significant Accounting Policies	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
	Interim Financial Data
	The interim financial data is unaudited; however, in the opinion of Omnicare management, all adjustments, consisting only of normal recurring adjustments, necessary for a fair statement of the Omnicare consolidated results of operations, financial position and cash flows for the interim periods presented have been made. All significant intercompany accounts and transactions have been eliminated.
	Stock-Based Compensation
	Stock-based compensation expense recognized in the Consolidated Statement of Comprehensive Income (Loss) for stock options, restricted stock units, performance share units and stock awards totaled approximately $5 million and $15 million, respectively, for the three and nine months ended September 30, 2014 and $5 million and $14 million for the three and nine months ended September 30, 2013, respectively.
	Accounts Receivable
	The following table is an aging of the Company’s gross accounts receivable (net of allowances for contractual adjustments), aged based on payment terms and categorized based on the three primary types of payors (in thousands):
	September 30, 2014		Current and 0-180 Days Past Due				181 Days and Over Past Due				Total
	Medicare (Part D and Part B), Medicaid and Third-Party payors		$	201,382			$	47,497			$	248,879
	Facility payors		306,681				122,378				429,059
	Private Pay payors		76,953				91,013				167,966
	Total gross accounts receivable		$	585,016			$	260,888			$	845,904
	December 31, 2013
	Medicare (Part D and Part B), Medicaid and Third-Party payors		$	195,544			$	67,791			$	263,335
	Facility payors		328,444				146,751				475,195
	Private Pay payors		75,655				84,101				159,756
	Total gross accounts receivable		$	599,643			$	298,643			$	898,286
	Accumulated Other Comprehensive Income (Loss)
	The following table is a summary of the Company’s accumulated other comprehensive income (loss) (“AOCI”) (in thousands):
			September 30,				December 31, 2013
			2014
	Unrealized loss on fair value of investments		$	(571	)		$	(702	)
	Pension and post-employment benefits		(1,364		)		(1,839		)
	Total accumulated other comprehensive loss, net		$	(1,935	)		$	(2,541	)
	The amounts are net of applicable tax benefits, which were not material at September 30, 2014 and December 31, 2013. The reclassifications out of AOCI did not materially affect any individual line item on the Consolidated Statement of Comprehensive Income (Loss).
	Fair Value
	The Company’s financial instruments, measured at fair value on a recurring basis, were as follows (in thousands):
							Based on
			Fair Value				Quoted Prices in Active Markets				Other Observable Inputs			Unobservable Inputs
							(Level 1)				(Level 2)			(Level 3)
	September 30, 2014
	Bond portfolio		$	25,216			$	—			$	25,216		$	—
	7.75% interest rate swap agreements - fair value hedge		18,041				—				18,041			—
	Derivatives		—				—				—			—
	Total		$	43,257			$	—			$	43,257		$	—
	December 31, 2013
	Bond portfolio		$	25,140			$	—			$	25,140		$	—
	7.75% interest rate swap agreements - fair value hedge		18,671				—				18,671			—
	Derivatives		—				—				—			—
	Total		$	43,811			$	—			$	43,811		$	—
	The fair value of the Company’s fixed-rate debt securities are shown in “Note 5 - Debt”.
	Offsetting Assets and Liabilities
	The Company has interest rate swap agreements (the “Interest Rate Swap Agreements”) with multiple counterparties with respect to all $400 million aggregate principle amount outstanding of its 7.75% Senior Subordinated Notes due 2020 (the “2020 Notes”). The following table presents the effect of netting arrangements on the Company’s recognized assets and liabilities in connection with the Interest Rate Swap Agreements as of September 30, 2014 and December 31, 2013 (in thousands):
											Gross Amounts not offset in the statement of financial position
	Interest Rate Swaps as of:	Gross amount of recognized assets (liabilities)			Gross amount offset in the statement of financial position			Net amount of assets (liabilities) presented in the statement of financial position			Financial instruments		Cash collateral received			Net amount
	30-Sep-14
	Swap A	$	9,130		$	—		$	9,130		$	—	$	—		$	9,130
	Swap B	8,911			—			8,911			—		—			8,911
		$	18,041		$	—		$	18,041		$	—	$	—		$	18,041
	December 31, 2013
	Swap A	$	9,408		$	—		$	9,408		$	—	$	—		$	9,408
	Swap B	9,263			—			9,263			—		—			9,263
		$	18,671		$	—		$	18,671		$	—	$	—		$	18,671
	Income Taxes
	The Company’s effective tax rate for the three and nine months ended September 30, 2014 and September 30, 2013 is different than the applicable federal statutory rate primarily as a result of the impact of state and local income taxes and additional tax benefits recognized in 2014 for prior year settlement payments, and the non-deductible portion of the settlement payments made related to the Gale and Silver complaints (each as described in “Note 7 - Commitments and Contingencies”).
	Other Charges
	Other charges (on a pre-tax basis) consist of the following (in thousands):
		Three months ended								Nine months ended
		September 30,								September 30,
		2014				2013				2014			2013
	Debt related costs	$	72			$	50,868			$	7,832		$	50,868
	Disposition of businesses	285				10,116				805			38,902
	Separation and other costs	3,642				648				16,922			4,836
	Acquisition and other related costs	—				—				—			2,300
Total - other charges	$	3,999			$	61,632			$	25,559		$	96,906
See “Note 5 - Debt” for additional details on the debt related costs.
Disposition of Businesses
In 2013, the Company completed the disposition of certain assets, primarily in its medical supply services business, which were not considered, individually or in the aggregate, significant to the operations of Omnicare. The Company recorded a charge on the disposition of these businesses of $10 million and $39 million ($9 million and $27 million after-tax), respectively, in the three and nine months ended September 30, 2013. These charges are reflected in the “Other charges” caption of the Consolidated Statement of Comprehensive Income (Loss).
Separation and Other Costs
In the three and nine months ended September 30, 2014, the Company recorded separation related costs and accelerated stock based compensation expense for certain employees of approximately $4 million and $17 million, respectively, including charges related to retirement of the Chief Executive Officer in the second quarter of 2014. In the three and nine months ended September 30, 2013, the Company recorded separation related costs for certain employees of approximately $1 million and $5 million, respectively. These charges are reflected in the “Other charges” caption of the Consolidated Statement of Comprehensive Income (Loss).
Restructuring and Other Related Charges
The Company continues to make payments in connection with its Company-wide Reorganization Program (the “CWR Program”), primarily related to certain severance amounts and the relocation of its corporate office. As of September 30, 2014, the Company has made cumulative payments of approximately $3 million for severance and other employee-related costs in connection with the CWR Program. The Company had liabilities related to the CWR Program of approximately $5 million at December 31, 2013, with utilization of approximately $2 million in the nine months ended September 30, 2014. The remaining liabilities pursuant to the CWR Program of $3 million at September 30, 2014, represent amounts not yet paid relating to actions taken in connection with the CWR Program (primarily lease termination costs) and will be settled as these matters are finalized.
Common Stock Repurchase Program
In the nine months ended September 30, 2014, the Company repurchased approximately 2.7 million shares of its common stock at an aggregate cost of approximately $160 million under share repurchase programs authorized by its Board of Directors. Through September 30, 2014, the Company has repurchased an aggregate of approximately 27 million shares of its common stock at an aggregate cost of approximately $1 billion under the share repurchase programs. During the nine months ended September 30, 2013, the Company repurchased approximately 2.5 million shares of its common stock at an aggregate cash outlay of approximately $91 million through authorized share repurchase programs. The cash expenditure in the nine months ended September 30, 2013 includes the impact of the equity forward contract components of the Company’s two previously disclosed accelerated share repurchase agreements. As of September 30, 2014, the Company had authority to repurchase approximately $340 million of additional shares under the share repurchase programs through December 31, 2015.
Capped Call
On April 2, 2012, the Company entered into capped call transactions with a counterparty, paying $48 million for the purchase of the capped calls, which was recorded as additional paid-in capital. The capped call transactions are intended to reduce potential economic dilution upon conversion of the Company’s 3.75% Convertible Senior Subordinated Notes due 2042. The capped calls settle in tranches through March 2016, one of which settled in the first quarter of 2014. The adjusted strike price for the capped calls ranged from $40.96 to $41.05 and the adjusted cap price for the tranche settled in 2014 ranged from $56.75 to $56.88; the strike and cap prices adjust for the Company’s dividend payments. The Company received approximately 0.6 million net shares upon settlement with a value of approximately $38 million.
Recently Issued Accounting Standards
In August 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”)2014-15, "Presentation of Financial Statements - Going Concern", which requires management to evaluate whether conditions or events raise substantial doubt about the entity’s ability to continue as a going concern and, if so, to provide related footnote disclosures. The guidance is effective for annual or interim reporting periods beginning on or after December 15, 2016. Early adoption is permitted. The Company does not expect the adoption of this ASU to have a material impact on the Company’s Consolidated Financial Statements.
In June 2014, the FASB issued ASU 2014-12, "Compensation - Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide that a Performance Target Could be Achieved after the Requisite Service Period," ("ASU 2014-12"). ASU 2014-12 requires that a performance target that affects vesting, and that could be achieved after the requisite service period, be treated as a performance condition. As such, the performance target should not be reflected in estimating the grant date fair value of the award. This update further clarifies that compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period(s) for which the requisite service has already been rendered. The guidance is effective for annual or interim reporting periods beginning on or after December 15, 2015. The Company does not anticipate that the adoption of this standard will have a material impact on its Consolidated Financial Statements.
In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers”, which provides guidance for revenue recognition. The standard’s core principle is that a company should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. This ASU also requires additional disclosures. ASU 2014-09 is effective for annual reporting periods beginning after December 15, 2016. The Company is currently in the process of evaluating the impact of adoption of this ASU on its Consolidated Financial Statements.
In April 2014, the FASB issued ASU No. 2014-08, “Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity”, which changes the criteria for determining which disposals can be presented as discontinued operations and modifies the related disclosure requirements. Under the new guidance, a disposal of a component of an entity or a group of components of an entity is required to be reported in discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity’s operations and financial results and is disposed of or classified as held for sale. The standard also introduces several new disclosures. The guidance applies prospectively to new disposals and new classifications of disposal groups as held for sale after the effective date. ASU 2014-08 is effective for annual and interim periods beginning after December 15, 2014, with early adoption permitted. The Company is currently in the process of evaluating the impact of adoption of this ASU on its Consolidated Financial Statements.

Discontinued_operations_Notes

Discontinued operations (Notes)	9 Months Ended
	Sep. 30, 2014
Discontinued operations [Abstract]	'
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]	'
	In the fourth quarter of 2013, the Company’s end-of-life hospice pharmacy business (“Hospice”) as well as certain retail operations (“Retail”) qualified for discontinued operations treatment. In the nine months ended September 30, 2014, the Company finalized the sale of Retail for net proceeds of approximately $6 million. In the three and nine months ended September 30, 2014, the Company finalized the sale of Hospice for net proceeds of approximately $65 million and recorded an after-tax loss of $4 million. Additionally, in the nine months ended September 30, 2014, the Company recorded an impairment loss, which was nondeductible for tax purposes, of $40 million to reduce the carrying value of Hospice to fair value. The results of operations for all periods presented reflect the results of Hospice and Retail as discontinued operations.
	Selected financial information related to the discontinued operations follows (in thousands):
		Three months ended September 30,						Nine months ended September 30,
		2014			2013			2014			2013
	Net Sales
	Hospice	$	25,163		$	52,774		$	123,071		$	158,240
	Retail	—			13,059			10,698			40,432
	Net sales - total discontinued	25,163			65,833			133,769			198,672
	Income (loss) from operations, pretax
	Hospice	(2,566		)	5,155			548			23,149
	Retail	104			(234		)	(1,546		)	(498		)
	Income (loss) from operations - total discontinued, pretax	(2,462		)	4,921			(998		)	22,651
	Income tax (benefit) expense
	Hospice	664			1,972			2,344			8,856
	Retail	120			(93		)	(761		)	(204		)
	Income tax (benefit) expense - total discontinued	784			1,879			1,583			8,652
	Income (loss) from operations of discontinued operations
	Hospice	(3,230		)	3,183			(1,796		)	14,293
	Retail	(16		)	(141		)	(785		)	(294		)
	Income (loss) from operations - total discontinued, after tax	(3,246		)	3,042			(2,581		)	13,999
	Impairment loss
	Hospice	—			—			39,804			—
	Retail	—			—			—			—
	Impairment loss on discontinued operations - total	—			—			39,804			$	—
	Income (loss) from discontinued operations
	Hospice	(3,230		)	3,183			(41,600		)	14,293
	Retail	(16		)	(141		)	(785		)	(294		)
	(Loss) income from discontinued operations - total	$	(3,246	)	$	3,042		$	(42,385	)	$	13,999

Goodwill_and_Other_Intangible_

Goodwill and Other Intangible Assets	9 Months Ended
	Sep. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Goodwill and Other Intangible Assets [Text Block]	'
	Changes in the carrying amount of goodwill for the nine months ended September 30, 2014 are as follows (in thousands):
		Long-Term Care Group			Specialty Care Group		Total
	Goodwill balance as of December 31, 2013	$	3,567,019		$	490,437	$	4,057,456
	Disposition of business	(41		)	—		(41		)
	Other	3,268			—		3,268
	Goodwill balance as of September 30, 2014	$	3,570,246		$	490,437	$	4,060,683
	“Other” includes adjustments made related to the final sales terms of the Retail divestiture, see “Note 3 - Discontinued Operations” for additional details.
	The Company’s intangible amortization expense for the three and nine months ended September 30, 2014 was approximately $8 million and $24 million, respectively, and approximately $8 million and $25 million for the three and nine months ended September 30, 2013, respectively.

Debt

Debt	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
Debt Disclosure [Text Block]	'
	The following table summarizes the Company’s debt (in thousands):
		September 30,			December 31,
		2014			2013
	Revolving credit facility, due 2017	$	—		$	—
	Senior term loan, due 2017	382,500			398,438
	7.75% senior subordinated notes, due 2020	400,000			400,000
	3.75% convertible senior subordinated notes, due 2025	79,979			132,408
	4.00% junior subordinated convertible debentures, due 2033	307,122			307,153
	3.25% convertible senior debentures, due 2035	427,500			427,500
	3.75% convertible senior subordinated notes, due 2042	390,000			390,000
	3.50% convertible senior subordinated notes, due 2044	424,250			424,250
	Capitalized lease and other debt obligations	14,906			20,685
	Subtotal	2,426,257			2,500,434
	Add interest rate swap agreements	18,041			18,671
	(Subtract) unamortized debt discount	(537,115		)	(573,082		)
	(Subtract) current portion of debt	(495,713		)	(527,204		)
	Total long-term debt, net	$	1,411,470		$	1,418,819
	Refinancing Activity
	In the second quarter of 2014, through privately negotiated transactions, Omnicare repurchased approximately $52 million in aggregate principal amount of its outstanding 3.75% Convertible Senior Subordinated Notes due 2025 (the “2025 Notes”) for approximately $134 million in cash. The Company recognized a loss on the repurchases of approximately $8 million in the second quarter of 2014, which is reflected in “Other charges” on the Consolidated Statement of Comprehensive Income (Loss).
	In the third quarter of 2013, Omnicare entered into separate, privately negotiated exchange agreements under which the Company retired approximately $180 million in aggregate principal amount of outstanding 2025 Notes in exchange for the issuance of $424 million in aggregate principal amount of new 3.50% Convertible Senior Subordinated Notes due 2044 (the "2044 Notes"). Additionally, the Company entered into separate, privately negotiated purchase agreements to repurchase approximately $5 million in aggregate principal amount of its outstanding 2025 Notes and $150 million in aggregate principal amount of its 2020 Notes. Operating income for the three and nine months ended September 30, 2013 includes a non-cash loss of approximately $51 million in connection with the 2013 refinancing activities which is reflected in “Other Charges” on the Consolidated Statement of Comprehensive Income (Loss).
	3.75% Convertible Senior Subordinated Notes, due 2025
	As of September 30, 2014, approximately $80 million aggregate principal amount of the 2025 Notes remained outstanding. Holders may convert their 2025 Notes, prior to December 15, 2023, on any date during any calendar quarter (and only during such calendar quarter) if the closing sale price of the Company’s common stock was more than 130% of the then current conversion price for at least 20 trading days in the period of the 30 consecutive trading days ending on, and including, the last trading day of the previous quarter, or at any time on or after December 15, 2023 or under certain other specified circumstances. Upon conversion, the Company will pay cash and shares of its common stock, if any, based on a daily conversion value calculated on a proportionate basis for each day of the applicable 25 trading-day cash settlement averaging period. The conversion price is $26.84 and the conversion threshold is $34.89 as of September 30, 2014. As of September 30, 2014 and December 31, 2013, the aforementioned conversion threshold had been attained. As a result, the 2025 Notes were convertible by the holders to cash and shares of the Company’s common stock and have been classified as current debt, net of discount, on the Consolidated Balance Sheet as of September 30, 2014 and December 31, 2013. Because the terms of the 2025 Notes require the principal to be settled in cash, the Company reclassified from equity the portion of the 2025 Notes attributable to the conversion feature that had not yet been accreted to its face value.
	4.00% Junior Subordinated Convertible Debentures, due 2033
	As of September 30, 2014, approximately $307 million aggregate principal amount of the Company’s 4.00% Junior Subordinated Convertible Debentures, due 2033 (the “2033 Debentures”) was outstanding. The 2033 Debentures underlie the 4.00% Trust Preferred Income Equity Redeemable Securities (“Trust PIERS”) of Omnicare Capital Trust I and Omnicare Capital Trust II (the “Series A Trust PIERS” and “Series B Trust PIERS”, respectively). Each Trust PIERS represents an undivided beneficial interest in the assets of the applicable trust, which assets consist solely of a corresponding amount of 2033 Debentures. The Series A Trust PIERS and the Series B Trust PIERS have identical terms, except that the Series B Trust PIERS have a net share settlement feature. Holders may convert their Trust PIERS if the closing sale price of the Company’s common stock was more than 130% of the then current conversion price for at least 20 trading days in the 30 consecutive trading day period ending on, and including, the last trading day of the previous quarter. The conversion price is $40.82 and the conversion threshold is $53.07 as of September 30, 2014. As of September 30, 2014 and December 31, 2013, the aforementioned conversion threshold had been attained. As a result, the Trust PIERS (and the underlying 2033 Debentures) were convertible by the holders and have been classified as current debt, net of discount, on the Consolidated Balance Sheet as of September 30, 2014 and December 31, 2013. Because the majority of the 2033 Debentures require the principal to be settled in cash, the Company reclassified from equity the portion attributable to the conversion feature that had not yet been accreted to its face value.
	The Trust PIERS (and underlying 2033 Debentures) have attained the threshold requiring payment of contingent interest in addition to regular cash interest.The contingent interest is accrued at the respective rate applied to the average trading price of the Trust PIERS for the five trading days ending on the respective date as outlined in the table below:
	Accrual Period			Contingent Interest Rate	Trading price period end date		Cash interest paid per $50 stated liquidation amount of Trust PIERS				Payment Date
	Start Date	End Date
	December 15, 2013	March 14, 2014		0.13%	December 12, 2013		$	0.09			March 17, 2014
	March 15, 2014	June 14, 2014		0.13%	March 13, 2014		$	0.09			June 16, 2014
	June 15, 2014	September 15, 2014		0.13%	June 12, 2014		$	0.09			September 15, 2014
	September 15, 2014	December 14, 2014		0.13%	September 12, 2014		$	0.1			December 15, 2014
	3.75% Convertible Senior Subordinated Notes, due 2042
	As of September 30, 2014, $390 million aggregate principal amount of 3.75% Convertible Senior Subordinated Notes due 2042 (the “2042 Notes”) was outstanding. Holders may convert their 2042 Notes, prior to April 1, 2040, on any date during any calendar quarter (and only during such calendar quarter) if the closing sale price of the Company’s common stock was more than 130% of the then current conversion price for at least 20 trading days in the 30 consecutive trading day period ending on, and including, the last trading day of the previous quarter, or at any time on or after April 1, 2040 or under certain other specified circumstances. Upon conversion, the Company will pay cash and shares of its common stock, if any, based on a daily conversion value calculated on a proportionate basis for each day of the applicable 25 trading-day cash settlement averaging period. The conversion price is $41.05 and the conversion threshold is $53.37 as of September 30, 2014. As of September 30, 2014 and December 31, 2013, the aforementioned conversion threshold had been attained. As a result, the 2042 Notes were convertible by the holders to cash and shares of the Company’s common stock and have been classified as current debt, net of discount, on the Consolidated Balance Sheet as of September 30, 2014 and December 31, 2013. Because the terms of the 2042 Notes require the principal to be settled in cash, the Company reclassified from equity the portion attributable to the conversion feature that had not yet been accreted to its face value.
	As outlined above, several series of the Company’s outstanding notes and debentures (collectively, the “Convertible Notes”) are convertible into cash and/or shares of Omnicare common stock under specified circumstances, including if the closing price of the Company’s common stock is more than 130% of the conversion price for such Convertible Notes during the applicable measurement period. In general, upon conversion, the Company will pay cash for the principal amount of the Convertible Notes and shares of common stock for the remainder, if any, based on a daily conversion value during the applicable cash settlement averaging period; provided that the Company will pay cash in lieu of any fractional shares. Payment occurs at the end of the applicable settlement period, which is generally 30 days after the Company receives a holder’s notice of conversion. As of September 30, 2014, approximately $777 million in aggregate principal amount of Convertible Notes were convertible, including the 2025 Notes, the 2042 Notes and the 2033 Debentures.
	The aggregate principle amount of Convertible Notes convertible at any given time is subject to change depending on factors such as the price of the Company’s common stock during the applicable measurement period. The Company cannot predict the aggregate principal amount of Convertible Notes that will be convertible at any given time or how many, if any, holders of such Convertible Notes will present their Convertible Notes for conversion or the impact of any such conversions on the Company’s results of operations, financial condition, liquidity or cash flows.
	Revolving Credit Facility and Term Loan
	As of September 30, 2014, there was $383 million outstanding under the Company’s term loan. The interest rate on the term loan was 1.91% at September 30, 2014. As of September 30, 2014, the Company had no outstanding borrowings under its revolving credit facility, except for approximately $14 million of standby letters of credit, substantially all of which are subject to automatic annual renewals.
	Interest Rate Swap Agreements
	The weighted average floating interest rate on the Interest Rate Swap Agreements in the third quarter of 2014 was 4.19% compared to the 7.75% stated interest rate on the corresponding 2020 Notes, which had a remaining principal balance of $400 million at September 30, 2014.
	Deferred Debt Issuance Costs
	The Company amortized to expense approximately $1 million of deferred debt issuance costs during each of the three month periods ended September 30, 2014 and 2013 and $3 million during each of the nine month periods ended September 30, 2014 and 2013, respectively. Interest expense for the nine months ended September 30, 2014 includes the write-off of approximately $1 million in deferred debt issuance costs related to the Company’s second quarter 2014 repurchase transaction. Interest expense for the three and nine months ended September 30, 2013 includes the write-off of approximately $5 million in deferred debt issuance costs related to the Company’s third quarter 2013 refinancing transactions activities.
	Information relating to the Company’s convertible securities at September 30, 2014 is in the following table:
	Convertible Debt	Carrying Value of Equity Component (in thousands)			Remaining Amortization Period		Effective Interest Rate
	3.75% convertible senior subordinated notes, due 2025	$	6,913		11.25		8.25	%
	4.00% junior subordinated convertible debentures, due 2033	$	118,348		18.75		8.01	%
	3.25% convertible senior debentures, due 2035	$	245,433		1.25		7.63	%
	3.75% convertible senior subordinated notes, due 2042	$	167,941		27.5		7.3	%
	3.50% convertible senior subordinated notes, due 2044	$	208,200		29.4		7.7	%
	The fair value of the Company’s fixed-rate debt facilities, excluding the Interest Rate Swap Agreements, is based on quoted market prices (Level II) and is summarized as follows (in thousands):
	Fair Value of Financial Instruments
		September 30, 2014							December 31, 2013
	Financial Instrument	Book Value			Market Value				Book Value			Market Value
	7.75% senior subordinated notes, due 2020	$	400,000		$	421,000			$	400,000		$	435,800
	3.75% convertible senior subordinated notes, due 2025
	Carrying value	53,801			—				87,310			—
	Unamortized debt discount	26,178			—				45,098			—
	Principal amount	79,979			180,800				132,408			306,500
	4.00% junior subordinated convertible debentures, due 2033
	Carrying value	188,124			—				186,136			—
	Unamortized debt discount	118,998			—				121,017			—
	Principal amount	307,122			468,300				307,153			455,900
	3.25% convertible senior debentures, due 2035
	Carrying value	405,419			—				393,126			—
Unamortized debt discount	22,081			—				34,374			—
Principal amount	427,500			450,000				427,500			457,400
3.75% convertible senior subordinated notes, due 2042
Carrying value	226,389			—				225,014			—
Unamortized debt discount	163,611			—				164,986			—
Principal amount	390,000			608,000				390,000			592,800
3.50% convertible senior subordinated notes, due 2044
Carrying value	218,003			—				216,643			—
Unamortized debt discount	206,247			—				207,607			—
Principal amount	424,250			469,600				424,250			428,500

Earnings_Loss_Per_Share_Data

Earnings (Loss) Per Share Data	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Earnings (Loss) Per Share Data	'
	The following is a reconciliation of the basic and diluted earnings per share (“EPS”) computations for both the numerator and denominator (in thousands, except per share data):
		Three months ended September 30,							Nine months ended September 30,
	2014:00:00	Income (Numerator)			Common Shares(Denominator)	Per Common			Income (Numerator)			Common Shares(Denominator)	Per Common
						Share Amounts							Share Amounts
	Basic EPS
	Income from continuing operations	$	68,077			$	0.7		$	192,961			$	1.98
	Loss from discontinued operations	(3,246		)		(0.03		)	(42,385		)		(0.43		)
	Net income	$	64,831		97,019	$	0.67		$	150,576		97,521	$	1.54
	Effect of Dilutive Securities
	Convertible securities	66			7,945				198			8,283
	Stock options, units and awards	—			584				—			646
	Diluted EPS
	Income from continuing operations plus assumed conversions	$	68,143			$	0.65		$	193,159			$	1.81
	Loss from discontinued operations	(3,246		)		(0.03		)	(42,385		)		(0.40		)
	Net income plus assumed conversions	$	64,897		105,548	$	0.61		$	150,774		106,450	$	1.42
		Three months ended September 30,							Nine months ended September 30,
	2013:00:00	Income (Numerator)			Common Shares(Denominator)	Per Common			Income (Numerator)			Common Shares(Denominator)	Per Common
						Share Amounts							Share Amounts
	Basic EPS
	Income (loss) from continuing operations	$	(69,351	)		$	(0.68	)	$	26,265			$	0.26
	Income from discontinued operations	3,042				0.03			13,999				0.14
	Net income (loss)	$	(66,309	)	101,811	$	(0.65	)	$	40,264		102,624	$	0.39
	Effect of Dilutive Securities
	Convertible securities	—			—				212			6,360
	Stock options, warrants, units and awards	—			—				—			628
	Diluted EPS
	Income (loss) from continuing operations plus assumed conversions	$	(69,351	)		$	(0.68	)	$	26,477			$	0.24
	Income from discontinued operations	3,042				0.03			13,999				0.13
	Net income (loss) plus assumed conversions	$	(66,309	)	101,811	$	(0.65	)	$	40,476		109,612	$	0.37
	EPS is reported independently for each amount presented. Accordingly, the sum of the individual amounts may not necessarily equal the separately calculated amounts for the corresponding period.
	The Company is required to include additional shares in its diluted shares outstanding calculation based on the treasury stock method when the average market price of a share of Omnicare stock on the New York Stock Exchange for the applicable period exceeds the following amounts:
	Convertible Debt	Price
	3.75% convertible senior subordinated notes, due 2025	$	26.84
	4.00% junior subordinated convertible debentures, due 2033	$	40.82
	3.25% convertible senior debentures, due 2035	$	77.88
	3.75% convertible senior subordinated notes, due 2042	$	41.05
	3.50% convertible senior subordinated notes, due 2044	$	70
	Diluted weighted average shares outstanding excludes the impact of 1 million stock options and stock awards for the nine months ended September 30, 2013 due to the exercise prices of these stock options and awards being greater than the average fair market value of our common stock during the period. The amount of stock options and stock awards excluded from the diluted weighted average shares outstanding for the three and nine months ended September 30, 2014 and the three months ended September 30, 2013 is immaterial.  Also, the Company has capped call provisions in place on our 3.75% convertible notes due 2042, which provide a hedge against economic dilution, but not against diluted share count under generally accepted accounting principles, up to an average stock price of approximately $68.75 through March 2016.

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	Omnicare evaluates contingencies on an ongoing basis in light of the best available information. The Company believes that it has recorded liabilities to the extent necessary if a material loss is considered probable and reasonably estimable. To the extent that the resolution of contingencies results in actual losses that differ from the Company’s recorded liabilities, future earnings will be charged or credited accordingly.
	On June 2, 2014, a complaint captioned Charles Lee on behalf of himself and all others similarly situated v. Omnicare, Inc., No. 14-CIV-1335 was filed against the Company in the U.S. District Court for the Southern District of California. The plaintiff brought the action individually and on behalf of a similarly situated class of plaintiffs. The plaintiff alleges that the Company violated the Telephone Consumer Protection Act (“TCPA”) by improperly calling cellular telephone numbers using an automatic telephone dialing system. On July 11, 2014, the Company filed an answer to the complaint. The Company denies the allegations in the complaint and intends to vigorously defend itself in this action.
	On March 21, 2014, a complaint entitled United States, et al., ex rel. Fox Rx, Inc. v. Dr. Reddy’s Inc., Omnicare, Inc., and NeighborCare, Inc., No. 13-CIV-3779 was served on Omnicare. The initial complaint was filed under seal on June 4, 2013 in the U.S. District Court for the Southern District of New York. The complaint was brought by Fox Rx., Inc. as a private party qui tam relator on behalf of the federal government and several states. The action alleges civil violations of the federal False Claims Act and analogous state laws based upon allegations that the Company entered into rebate arrangements with a manufacturer of generic simvastatin allegedly in violation of the Anti-Kickback Statute and that the Company improperly charged certain dispensing fees to Medicare Part D. The U.S. Department of Justice has notified the court that it declined to intervene in this action. On June 17, 2014, the Company filed a motion to dismiss the First Amended Complaint. On July 7, 2014, Relator filed a Second Amended Complaint in response to the motion to dismiss. On August 8, 2014, the Company moved to dismiss the Second Amended Complaint. The Company believes that the allegations are without merit and intends to vigorously defend itself in this action.
	On November 26, 2013, a complaint entitled United States, et al., ex rel. Frank Kurnik v. Amgen, Inc., Omnicare, Inc., PharMerica Corp., and Kindred Healthcare, Inc., No. 3:11-cv-01464-JFA, was unsealed by the U.S. District Court for the District of South Carolina. The U.S. Department of Justice has notified the court that it intervened against Omnicare for the purposes of settlement. The complaint alleges violations of the False Claims Act stemming from activities in connection with agreements it had with the manufacturer of the pharmaceutical Aranesp that allegedly violated the Anti-Kickback Statute. In a previous filing, prior to the complaint being unsealed, the Company disclosed the underlying investigation by the U.S. Department of Justice, through the U.S. Attorney’s Office for the District of South Carolina. The Company previously recorded a provision related to this matter. On February 27, 2014, the Company agreed to a settlement of this matter in exchange for a payment of $4.2 million, which was accrued as of December 31, 2013 and paid in the first half of 2014. On February 28, 2014, the Court dismissed this case with prejudice.
	On November 18, 2013, a complaint entitled United States, et al., ex rel. Fox Rx, Inc. v. Omnicare, Inc., NeighborCare, Inc., PharMerica Corporation, and Managed Health Care Associates, Inc., No. 1:12-CIV-0275 was served on Omnicare. The initial complaint was filed under seal on January 12, 2012 in the U.S. District Court for the Southern District of New York. The complaint was brought by Fox Rx., Inc. as a private party qui tam relator on behalf of the federal government and several states. The action alleges civil violations of the federal False Claims Act and analogous state laws based upon allegations that the Company dispensed certain brand medications in lieu of generic alternatives in violation of state board of pharmacy regulations or state Medicaid laws, and allegations that the Company dispensed expired medications in violation of Medicare regulations. The U.S. Department of Justice has notified the court that it declined to intervene in this action. On February 7, 2014, the relator filed a Second Amended Complaint. On February 28, 2014, the Company filed a motion to dismiss the Second Amended Complaint. On August 12, 2014, the court granted the Company’s motion to dismiss and entered an order dismissing with prejudice all claims against the Company.
	On July 29, 2013, a complaint entitled James D. “Buddy” Caldwell, Attorney General, ex rel. State of Louisiana v. Abbott Laboratories, Inc., et al., No. 603091, was served on Omnicare. The initial complaint was first filed against Abbott on June 30, 2011. Omnicare and other defendants were added on July 9, 2013. The complaint was brought by the Louisiana Attorney General alleging that certain activities in connection with agreements Omnicare had with Abbott, the manufacturer of the pharmaceutical Depakote, violated the Louisiana Medical Assistance Program Integrity Laws and Unfair Trade Practices Act. On August 27, 2013, the Company removed this action to the United States District Court for the Middle District of Louisiana. On September 26, 2013, the State moved to remand the case to state court. The Company opposed the motion. On September 23, 2014, the Court remanded the case to state court. The Company believes that the allegations are without merit and intends to vigorously defend itself in this action.
	On May 23, 2013, a qui tam complaint entitled United States and the State of Illinois ex rel. Alan Litwiller v. Omnicare, Inc., No. 1:11-cv-08980, was unsealed by the U.S. District Court for the Northern District of Illinois, Eastern Division. The complaint was brought by Alan Litwiller as a private party qui tam relator on behalf of the federal government and the State of Illinois. The action alleges civil violations of the federal False Claims Act and analogous Illinois state law based upon allegations that the Company agreed to forego collection of certain debts, provided certain credits or refunds to customers, provided charitable donations to charities associated with certain customers, and provided other services below cost for referrals of business in violation of the Anti-Kickback Statute. The U.S. Department of Justice has notified the court that it declined to intervene in this action. On September 16, 2013, the Company filed a motion to dismiss the relator’s claims. On April 14, 2014, the court granted in part and denied in part the Company’s motion to dismiss. On June 17, 2014, the Company and Relator reached an agreement in principle to a dismissal of this matter. On August 4, 2014, the Court dismissed this matter with prejudice.
	On March 22, 2013, a qui tam complaint entitled United States et al. ex rel. Susan Ruscher v. Omnicare, Inc. et al., Civil No. 08-cv-3396, which had been filed under seal in the U.S. District Court for the Southern District of Texas, was unsealed by the court. The complaint was brought by Susan Ruscher as a private party qui tam relator on behalf of the federal government and several state governments. The action alleges civil violations of the federal False Claims Act and analogous state laws based upon allegations that the Company’s practices relating to customer collections violated the Anti-Kickback Statute. The U.S. Department of Justice has notified the court that it declined to intervene in this action at this time. On September 6, 2013, the relator filed a Third Amended Complaint. On November 5, 2013, the Company filed a motion to dismiss the Third Amended Complaint. On June 12, 2014, the court granted in part and denied in part the motion to dismiss. On July 14, 2014, the Company filed an answer to the Third Amended Complaint. The Company believes that the allegations are without merit and intends to vigorously defend itself in this action.
	On March 11, 2013, a qui tam complaint entitled United States et al. ex rel. Marc Silver v. Omnicare, Inc. et al. Civil No. 1:11-cv-01326, which had been filed under seal in the U.S. District Court for the District of New Jersey, was unsealed by the court. The complaint was brought by Marc Silver as a private party qui tam relator on behalf of the federal government and several state governments. The action alleges civil violations of the federal False Claims Act and analogous state laws based upon allegations that the Company provided certain customer facilities with discounts and other forms of remuneration in return for referrals of business in violation of the Anti-Kickback Statute. The U.S. Department of Justice has notified the court that it declined to intervene in this action. On August 30, 2013, the Company filed a motion to dismiss the complaint. On October 22, 2013, as part of the agreement in principle to settle the claims alleged in the Gale complaint (as described below), the Company agreed with the relator to settle certain federal claims alleged in the Silver complaint. The agreement in principle was not effectuated. On November 12, 2013, the relator filed his Third Amended Complaint and on December 6, 2013, the Company filed a Motion to Dismiss the Third Amended Complaint. On January 24, 2014, as part of the revised agreement in principle to settle the claims alleged in the Gale complaint, the Company agreed to pay $8.24 million and no attorneys’ fees to settle all state claims in the Silver complaint and the U.S. Department of Justice agreed to have all federal claims in the Silver complaint dismissed with prejudice. This agreement in principle relating to the claims in the Gale complaint and the federal claims in the Silver complaint was executed by the federal government, the Company, relators and relators’ counsel on June 24, 2014. The agreements in principle relating to the state claims were executed by each state named in the Silver complaint except for the State of Hawaii. On September 16, 2014, the court entered an order dismissing the Company from the case with prejudice.
	On October 5, 2011, a qui tam complaint, entitled United States ex rel. Donald Gale v. Omnicare, Inc., No. 1:10-cv-0127, was served on the Company. The case had been filed on January 19, 2010 under seal with the U.S. District Court for the Northern District of Ohio, Eastern Division. The complaint was unsealed by the court on June 9, 2011 after the U.S. Department of Justice notified the court that it has declined to intervene in this action. The complaint was brought by Donald Gale as a private party qui tam relator on behalf of the federal government. The action alleges civil violations of the False Claims Act based on allegations that the Company provided certain customer facilities with discounts and other forms of remuneration in return for referrals of business in violation of the Anti-Kickback Statute, and offered pricing terms in violation of the “most favored customer” pricing laws of various state Medicaid plans. The Company filed a motion to dismiss on January 27, 2012. On September 26, 2012, the court granted in part and denied in part the Company’s motion to dismiss. On October 22, 2013, the Company reached an agreement in principle, without admitting liability, with the relator, pursuant to which the Company agreed to pay $120 million, plus attorneys’ fees, to settle the relator’s alleged claims, as well as certain claims alleged in the Silver complaint (described above). On December 6, 2013, after approval by the U.S. Department of Justice, the Company and the relator executed settlement documentation. Prior to the case being dismissed, the court learned of a potential breach of the seal by the relator and potential misrepresentations by the relator and his attorneys and held a hearing on January 9, 2014 to reconsider the court’s prior order denying the Company’s motion for disqualification of the relator and dismissal of the action and the Company’s additional motion for sanctions. Prior to the court’s decision on the reconsideration motion and a motion for sanctions against the relator and his attorneys, on January 24, 2014, the Company reached an agreement in principle, without admitting liability, with the U.S. Department of Justice (which was granted leave to intervene on February 20, 2014), in which the Company agreed to pay $116 million and no attorneys’ fees to settle the claims alleged in the Gale complaint and to pay $8.24 million and no attorneys’ fees to settle all the state claims alleged in the Silver complaint and the U.S. Department of Justice agreed to have federal claims alleged in the Silver complaint dismissed with prejudice. In addition, the Company and the relator reached an agreement in principle pursuant to which the relator will pay the Company $4.24 million to settle the motion for sanctions. These agreements in principle relating to the claims in the Gale complaint and the federal claims in the Silver complaint were executed by the federal government, the Company, the relators and relators’ counsel on June 24, 2014. The agreements in principle relating to the state claims in Silver were executed by each state named in the Silver complaint except for the State of Hawaii. The Company recorded a provision equal to the net settlement amount and an estimate of legal fees in its financial results for the year ended December 31, 2013. During the third quarter of 2014, settlement payments of $116 million and $8.24 million were made related to the Gale and Silver complaints, respectively, and $4.24 million was received related to the motion for sanctions filed by the Company against relator Gale and his attorneys. On August 11, 2014, the court entered an order dismissing with prejudice all claims against the Company.
	On August 24, 2011, a class action complaint entitled Ansfield v. Omnicare, Inc., et al. was filed on behalf of a putative class of all purchasers of the Company’s common stock from January 10, 2007 through August 5, 2010 against the Company and certain of its current and former officers in the U.S. District Court for the Eastern District of Kentucky, alleging violations of federal securities laws in connection with alleged false and misleading statements with respect to the Company’s compliance with federal and state Medicare and Medicaid laws and regulations. On October 21, 2011, a class action complaint entitled Jacksonville Police & Fire Pension Fund v. Omnicare, Inc. et al. was filed on behalf of the same putative class of purchasers as is referenced in the Ansfield complaint, against the Company and certain of its current and former officers, in the U.S. District Court for the Eastern District of Kentucky. Plaintiffs allege substantially the same violations of federal securities law as are alleged in the Ansfield complaint. Both complaints seek unspecified money damages. The court has appointed lead counsel and a consolidated amended complaint was filed on May 11, 2012. The Company filed a motion to dismiss on July 16, 2012. On March 27, 2013, the court granted the Company’s motion to dismiss and dismissed all claims with prejudice. On April 26, 2013, the plaintiffs filed a notice of appeal to the U.S. Court of Appeals for the Sixth Circuit appealing the District Court’s order dismissing the complaint with prejudice. The parties completed oral argument before the Sixth Circuit on January 30, 2014. On October 10, 2014, the Court of Appeals for the Sixth Circuit affirmed the District Court’s dismissal with prejudice.
	On October 29, 2010, a qui tam complaint entitled United States et al., ex rel. Banigan and Templin v. Organon USA, Inc., Omnicare, Inc. and PharMerica Corporation, Civil No. 07-12153-RWZ, that had been filed under seal with the U.S. District Court in Boston, Massachusetts, was ordered unsealed by the court. The complaint was brought by James Banigan and Richard Templin, former employees of Organon, as private party qui tam relators on behalf of the federal government and several state and local governments. The action alleges civil violations of the False Claims Act based on allegations that Organon USA, Inc. and its affiliates paid the Company and several other long-term care pharmacies rebates, post-purchase discounts and other forms of remuneration in return for purchasing pharmaceuticals from Organon and taking steps to increase the purchase of Organon’s drugs in violation of the Anti-Kickback Statute. The U.S. Department of Justice declined to intervene in this action. The court denied the Company’s motion to dismiss on June 1, 2012. Discovery is ongoing in this matter. The Company believes that the allegations are without merit and intends to vigorously defend itself in this action.
	The U.S. Department of Justice, through the U.S. Attorney’s Office for the Western District of Virginia, is investigating whether the Company’s activities in connection with the agreements it had with the manufacturer of the pharmaceutical Depakote violated the False Claims Act or the Anti-Kickback Statute. The Company is cooperating with this investigation and believes that it has complied with applicable laws and regulations with respect to this matter. In connection with this matter, on May 29, 2014, the United States District Court for the Western District of Virginia entered an order unsealing two previously partially sealed qui tam complaints, entitled United States, et al., ex rel. Spetter v. Abbott Laboratories. Inc., Omnicare, Inc., and PharMerica Corp., No. 1:07-cv-00006 and United States, et al., ex rel. McCoyd v. Abbott Laboratories, Omnicare, Inc., PharMerica Corp., and Miles White, No. 1:07-cv-0008, and the United States’ Notice of Intervention in the cases. The complaints allege violations of the False Claims Act stemming from activities in connection with agreements the Company had with the manufacturer of the pharmaceutical Depakote that allegedly violated the Anti-Kickback Statute. The Company believes that the allegations are without merit and intends to vigorously defend itself in this action.
	The U.S. Department of Justice is investigating whether certain of the Company’s practices relating to customer collections violated the False Claims Act or the Anti-Kickback Statute. The Company is cooperating with this investigation and believes that it has complied with applicable laws and regulations with respect to this matter.
	On November 19, 2010, the Company was served with a second amended qui tam complaint entitled United States ex rel. Rostholder v. Omnicare, Inc. and Omnicare Distribution Center, LLC f/k/a Heartland Repack Services LLC, No. CCB-07-1283, which was filed under seal with the U.S. District Court in Baltimore, Maryland in May 2007. The U.S. Department of Justice notified the court on April 22, 2009 that it declined to intervene in this action. The complaint was brought by Barry Rostholder as a private party qui tam relator on behalf of the federal government and several state and local governments. The action, in general, alleges civil violations of the False Claims Act based on allegations that the Company submitted claims for reimbursement for drugs that were repackaged at its Heartland repackaging facility in violation of certain FDA regulations. These allegations arise from the previously disclosed issues experienced by the Company at its Heartland repackaging facility, which suspended operations in 2006. On September 30, 2011, the Company filed a motion to dismiss the lawsuit in its entirety. On August 14, 2012, the court granted the Company’s motion with prejudice as to the relator and without prejudice as to the United States. The relator filed an amended motion for reconsideration on September 10, 2012. On October 19, 2012, the court denied the relator’s motion to reconsider. On November 16, 2012, the relator filed a Notice of Appeal to the U.S. Court of Appeals for the Fourth Circuit from the District Court’s denial of the motion to reconsider and granting of the Company’s motion to dismiss. On February 21, 2014, the U.S. Court of Appeals for the Fourth Circuit upheld the United States District Court’s dismissal of the lawsuit with prejudice. On May 22, 2014, relator filed a petition for writ of certiorari in the United States Supreme Court. On October 6, 2014, the Supreme Court denied relator’s petition for writ of certiorari.
	As part of the previously disclosed civil settlement agreement entered into by the Company with the U.S. Attorney’s Office, District of Massachusetts in November 2009, the Company also entered into an amended and restated corporate integrity agreement (“CIA”) with the Department of Health and Human Services Office of the Inspector General (“OIG”) with a term of five years from November 2, 2009. Pursuant to the CIA, the Company is required, among other things, to (i) create procedures designed to ensure that each existing, new or renewed arrangement with any actual or potential source of health care business or referrals to Omnicare or any actual or potential recipient of health care business or referrals from Omnicare does not violate the Anti-Kickback Statute, 42 U.S.C. (§) 1320a-7b(b) or related regulations, directives and guidance, including creating and maintaining a database of such arrangements; (ii) retain an independent review organization to review the Company’s compliance with the terms of the CIA and report to OIG regarding that compliance; and (iii) provide training for certain Company employees as to the Company’s requirements under the CIA. The requirements of the Company’s prior corporate integrity agreement obligating the Company to create and maintain procedures designed to ensure that all therapeutic interchange programs are developed and implemented by Omnicare consistent with the CIA and federal and state laws for obtaining prior authorization from the prescriber before making a therapeutic interchange of a drug and to maintain procedures for the accurate preparation and submission of claims for federal health care program beneficiaries in hospice programs, have been incorporated into the amended and restated CIA without modification. The requirements of the CIA have resulted in increased costs to maintain the Company’s compliance program and greater scrutiny by federal regulatory authorities. Violations of the CIA could subject the Company to significant monetary penalties. The OIG is currently seeking information concerning the Company’s compliance programs and policies and its arrangements. Consistent with the CIA, the Company is reviewing its contracts to ensure compliance with applicable laws and regulations. As a result of this review, pricing under certain of its consultant pharmacist services contracts has increased and will continue to increase.
	In February 2006, two substantially similar putative class action lawsuits were filed in the U.S. District Court for the Eastern District of Kentucky, and were consolidated and entitled Indiana State Dist. Council of Laborers & HOD Carriers Pension & Welfare Fund v. Omnicare, Inc., et al., No. 2:06cv26. The amended consolidated complaint was filed against Omnicare, three of its officers and two of its directors and purported to be brought on behalf of all open-market purchasers of Omnicare common stock from August 3, 2005 through July 27, 2006, as well as all purchasers who bought shares of Omnicare common stock in the Company’s public offering in December 2005. The complaint contained claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (and Rule 10b-5 thereunder) and Section 11 of the Securities Act of 1933 and sought, among other things, compensatory damages and injunctive relief. Plaintiffs alleged that Omnicare (i) artificially inflated its earnings (and failed to file GAAP-compliant financial statements) by engaging in improper generic drug substitution, improper revenue recognition and overvaluation of receivables and inventories; (ii) failed to timely disclose its contractual dispute with UnitedHealth Group Inc.; (iii) failed to timely record certain special litigation reserves; and (iv) made other allegedly false and misleading statements about the Company’s business, prospects, and compliance with applicable laws and regulations. The defendants filed a motion to dismiss the amended complaint on March 12, 2007, and on October 12, 2007, the district court dismissed the case. On November 9, 2007, plaintiffs appealed the dismissal to the U.S. Court of Appeals for the Sixth Circuit. On October 21, 2009, the Sixth Circuit Court of Appeals generally affirmed the district court’s dismissal, dismissing plaintiff’s claims for violation of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder. However, the appellate court reversed the dismissal for the claim brought for violation of Section 11 of the Securities Act of 1933, and returned the case to the district court for further proceedings. On July 14, 2011, the district court granted plaintiffs’ motion to file a third amended complaint. This complaint asserts a claim under Section 11 of the Securities Act of 1933 on behalf of all purchasers of Omnicare common stock in the December 2005 public offering. The new complaint alleges that the 2005 registration statement contained false and misleading statements regarding Omnicare’s policy of compliance with all applicable laws and regulations with particular emphasis on allegations of violation of the federal Anti-Kickback Statute in connection with three of Omnicare’s acquisitions, Omnicare’s contracts with two of its suppliers, and its provision of pharmacist consultant services. On August 19, 2011, the defendants filed a motion to dismiss the plaintiffs’ most recent complaint and on February 13, 2012 the district court dismissed the case and struck the case from the docket. On March 12, 2012, the plaintiffs filed a notice of appeal in the U.S. Court of Appeals for the Sixth Circuit. On May 23, 2013, the U.S. Court of Appeals affirmed in part and reversed and remanded in part the dismissal of the plaintiffs’ complaint. On June 6, 2013, the Company petitioned the Court of Appeals for a rehearing en banc. The petition for rehearing en banc was denied on July 23, 2013. On October 4, 2013, the Company filed a petition for writ of certiorari in the United States Supreme Court. On March 3, 2014, the United States Supreme Court granted the Company’s petition for writ of certiorari. On June 5, 2014, the Company filed its Brief in Support of Appeal in the United States Supreme Court. Oral argument at the United States Supreme Court is scheduled for November 3, 2014.
	For the three and nine months ended September 30, 2014, charges of approximately $13 million and $27 million, respectively, and approximately $143 million and $170 million for the three and nine months ended September 30, 2013, respectively, were included in “Settlement, litigation and other related charges” on the Consolidated Statement of Comprehensive Income (Loss), primarily for estimated litigation and other related settlements and associated professional expenses for resolution of certain large customer disputes, certain regulatory matters with the federal government and various states, qui tam lawsuits, and costs associated with the purported class and derivative actions against the Company. In connection with Omnicare’s participation in Medicare, Medicaid, and other healthcare programs, the Company is subject to various inspections, audits, inquiries, and investigations by governmental/regulatory authorities responsible for enforcing the laws and regulations to which the Company is subject. Further, the Company maintains a compliance program which establishes certain routine periodic monitoring of the accuracy of the Company’s billing systems and other regulatory compliance matters and encourages the reporting of errors and inaccuracies. In connection with its compliance program, Omnicare has made, and will continue to make, disclosures to the applicable governmental agencies of amounts, if any, determined to represent over-payments from the respective programs and, where applicable, those amounts, as well as any amounts relating to certain inspections, audits, inquiries, and investigations activity are included in “Settlement, litigation and other related charges” on the Consolidated Statement of Comprehensive Income (Loss).
	The Company cannot know the ultimate outcome of the pending matters described in the preceding paragraphs, and there can be no assurance that the resolution of these matters will not have a material adverse impact on the Company’s consolidated results of operations, financial position or cash flows or, in the case of other billing matters, that these matters will be resolved in an amount that will not exceed the amount of the pretax charges previously recorded by the Company.
	As part of its ongoing operations, the Company is subject to various inspections, audits, inquiries, investigations, and similar actions by third parties, as well as by governmental/regulatory authorities responsible for enforcing certain laws and regulations to which the Company is subject. Further, under the federal False Claims Act, private parties have the right to bring qui tam, or “whistleblower,” suits against companies that submit false claims for payments to, or improperly retain overpayments from, the government. Some states have adopted similar state whistleblower and false claims provisions. In addition to the inquiries discussed above, the Company from time to time receives inquiries from federal and state agencies regarding compliance with various healthcare laws. The Company is also involved in various legal actions arising in the normal course of business. At any point in time, the Company is in varying stages of discussions on these matters. The Company evaluates these matters on an ongoing basis and records accruals for such contingencies if the Company concludes that it is probable that a material loss will be incurred and the amount of the loss can be reasonably estimated. In many situations, these matters are being contested by the Company, the outcome is not predictable and any potential loss is not estimable.
	The inherently unpredictable nature of legal proceedings may be exacerbated by various factors from time to time, including: (i) the damages sought in the proceedings are unsubstantiated or indeterminate; (ii) discovery is not complete; (iii) the proceeding is in its early stages; (iv) the matters present legal uncertainties; (v) significant facts are in dispute; (vi) a large number of parties are participating in the proceedings (including where it is uncertain how liability, if any, will be shared among multiple defendants); or (vii) the proceedings present a wide range of potential outcomes. With respect to violations of the False Claims Act, treble damages and/or additional penalties per claim will apply. Consequently, unless otherwise stated, no estimate of the possible loss or range of loss in excess of the amounts accrued, if any, can be made at this time regarding the pending matters described above. Further, there can be no assurance that the ultimate resolution of these matters, individually or in the aggregate, will not have a material adverse effect on the Company’s consolidated results of operations, financial position or cash flows.
	The Company indemnifies its directors and officers for certain liabilities that might arise from the performance of their responsibilities for the Company.  Additionally, in the normal course of its business, the Company enters into contracts pursuant to which the Company may make a variety of representations and warranties and indemnify the counterparty for certain losses.  The Company’s possible exposure under these arrangements cannot be reasonably estimated, as this involves the resolution of claims made, or future claims that may be made, against the Company or its directors or officers, the outcomes of which are unknown and not currently predictable.  Accordingly, the Company has not recorded any accrual related to its indemnification obligations.

Segment_Information

Segment Information	9 Months Ended
	Sep. 30, 2014
Segment Reporting [Abstract]	'
Segment Information	'
	The Company is organized in two operating segments, Long-Term Care Group (“LTC”) and Specialty Care Group (“SCG”). These segments are based on the operations of the underlying businesses and the customers they serve. The Company’s larger reportable segment is LTC, which primarily provides distribution of pharmaceuticals, related pharmacy consulting and other ancillary services. LTC’s customers are primarily skilled nursing, assisted living and other providers of healthcare services. The Company’s other reportable segment is SCG, which provides specialty pharmacy and key commercialization services for the biopharmaceutical industry. The primary components of the “Corporate/Other” segment are the Company’s corporate management oversight and administration, including its information technology and data management services, as well as other consolidating and eliminating entries, which have not been charged to reportable segments. The Company evaluates the performance of its segments based on revenue and operating income, and does not include segment assets or nonoperating income/expense items for management reporting purposes.
	(In thousands)	For the three months ended September 30,
	2014:00:00	LTC			SCG			Corporate/Other			Consolidated
											Totals
	Net sales	$	1,183,398		$	424,580		$	77		$	1,608,055
	Depreciation and amortization expense	(17,405		)	(1,078		)	(14,849		)	(33,332		)
	Settlement, litigation and other related charges	(12,868		)	—			—			(12,868		)
	Other charges	(3,553		)	—			(446		)	(3,999		)
	Operating income (loss)	142,285			34,203			(40,746		)	135,742
	2013:00:00
	Net sales	$	1,157,951		$	357,057		$	160		$	1,515,168
	Depreciation and amortization expense	(17,919		)	(1,168		)	(14,953		)	(34,040		)
	Settlement, litigation and other related charges	(143,484		)	—			—			(143,484		)
	Other charges	(10,764		)	—			(50,868		)	(61,632		)
	Operating income (loss)	4,207			26,845			(91,828		)	(60,776		)
		For the nine months ended September 30,
	2014:00:00	LTC			SCG			Corporate/Other			Consolidated
											Totals
	Net sales	$	3,565,092		$	1,224,319		$	266		$	4,789,677
	Depreciation and amortization expense	(52,258		)	(3,373		)	(44,798		)	(100,429		)
	Settlement, litigation and other related charges	(27,467		)	—			—			(27,467		)
	Other charges	(8,984		)	—			(16,575		)	(25,559		)
	Operating income (loss)	444,402			97,057			(142,719		)	398,740
	2013:00:00
	Net sales	$	3,458,772		$	1,017,127		$	1,330		$	4,477,229
	Depreciation and amortization expense	(53,801		)	(3,408		)	(42,318		)	(99,527		)
	Settlement, litigation and other related charges	(169,615		)	—			—			(169,615		)
	Other charges	(44,065		)	—			(52,841		)	(96,906		)
	Operating income (loss)	259,953			82,005			(187,678		)	154,280

Guarantor_Subsidiaries

Guarantor Subsidiaries	9 Months Ended
	Sep. 30, 2014
Guarantor Subsidiaries [Abstract]	'
Schedules Of Condensed Financial Statements [Text Block]	'
	The 2020 Notes, the 2025 Notes, the 2042 Notes, and the Company’s 3.50% Convertible Senior Subordinated Notes, due 2044 are fully and unconditionally guaranteed, subject to certain customary release provisions, on an unsecured, joint and several basis by certain 100% owned subsidiaries of the Company (the “Guarantor Subsidiaries”). The following condensed consolidating unaudited financial data illustrates the composition of Omnicare, Inc. (“Parent”), the Guarantor Subsidiaries and the Non-Guarantor Subsidiaries as of September 30, 2014 and December 31, 2013 for the balance sheets, as well as the three and nine months ended September 30, 2014 and 2013 for the statements of comprehensive income (loss) and the statements of cash flows. In connection with the sale of Hospice in the third quarter of 2014, the results of the Hospice operations have been reclassified as Non-Guarantor Subsidiaries for all periods presented (see “Note 3 - Discontinued Operations” for additional details on the sale of Hospice). Management believes separate complete financial statements of the Guarantor Subsidiaries would not provide information that would be necessary for evaluating the sufficiency of the Guarantor Subsidiaries, and thus are not presented. The equity method has been used with respect to the Parent company’s investment in subsidiaries. No consolidating/eliminating adjustment column is presented for the condensed consolidating statements of cash flows since there were no significant consolidating/eliminating adjustment amounts during the periods presented.
	Summary Consolidating
	Statements of Comprehensive Income (Loss)
	(in thousands)
		For the three months ended September 30,
	2014:00:00	Parent			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Consolidating /			Omnicare, Inc. and Subsidiaries
											Eliminating Adjustments
	Net sales	$	—		$	1,576,811		$	31,244		$	—		$	1,608,055
	Cost of sales	—			1,236,644			19,951			—			1,256,595
	Gross profit	—			340,167			11,293			—			351,460
	Selling, general and administrative expenses	1,053			172,857			5,030			—			178,940
	Provision for doubtful accounts	—			19,570			341			—			19,911
	Settlement, litigation and other related charges	—			12,868			—			—			12,868
	Other charges	—			3,999			—			—			3,999
	Operating income (loss)	(1,053		)	130,873			5,922			—			135,742
	Interest expense, net of investment income	(28,456		)	(261		)	—			—			(28,717		)
	Income (loss) before income taxes	(29,509		)	130,612			5,922			—			107,025
	Income tax (benefit) expense	(11,503		)	48,139			2,312			—			38,948
	Income (loss) from continuing operations	(18,006		)	82,473			3,610			—			68,077
	Loss from discontinued operations	—			(526		)	(2,720		)	—			(3,246		)
	Equity of net income of subsidiaries	82,837			—			—			(82,837		)	—
	Net income	$	64,831		$	81,947		$	890		$	(82,837	)	$	64,831
	Comprehensive income	$	65,170		$	81,947		$	890		$	(82,837	)	$	65,170
	2013:00:00
	Net sales	$	—		$	1,485,545		$	29,623		$	—		$	1,515,168
	Cost of sales	—			1,146,140			17,057			—			1,163,197
	Gross profit	—			339,405			12,566			—			351,971
	Selling, general and administrative expenses	1,504			176,970			4,194			—			182,668
	Provision for doubtful accounts	—			24,487			476			—			24,963
	Settlement, litigation and other related charges	—			143,484			—			—			143,484
	Other charges	—			54,361			7,271			—			61,632
	Operating income (loss)	(1,504		)	(59,897		)	625			—			(60,776		)
	Interest expense, net of investment income	(34,583		)	(344		)	2			—			(34,925		)
	Income (loss) before income taxes	(36,087		)	(60,241		)	627			—			(95,701		)
	Income tax (benefit) expense	(14,190		)	(15,270		)	3,110			—			(26,350		)
	Income (loss) from continuing operations	(21,897		)	(44,971		)	(2,483		)	—			(69,351		)
	Income (loss) from discontinued operations	—			(2,100		)	5,142			—			3,042
	Equity of net income of subsidiaries	(44,412		)	—			—			44,412			—
	Net loss	$	(66,309	)	$	(47,071	)	$	2,659		$	44,412		$	(66,309	)
	Comprehensive loss	$	(66,305	)	$	(47,071	)	$	2,659		$	44,412		$	(66,305	)
	Note 9 - Guarantor Subsidiaries (Continued)
	Summary Consolidating
	Statements of Comprehensive Income (Loss)
	(in thousands)
		For the nine months ended September 30,
	2014:00:00	Parent			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Consolidating /			Omnicare, Inc. and Subsidiaries
											Eliminating Adjustments
	Net sales	$	—		$	4,697,025		$	92,652		$	—		$	4,789,677
	Cost of sales	—			3,669,163			56,370			—			3,725,533
	Gross profit	—			1,027,862			36,282			—			1,064,144
	Selling, general and administrative expenses	3,481			531,899			14,436			—			549,816
	Provision for doubtful accounts	—			61,202			1,360			—			62,562
	Settlement, litigation and other related charges	—			27,467			—			—			27,467
	Other charges	—			25,559			—			—			25,559
	Operating income (loss)	(3,481		)	381,735			20,486			—			398,740
	Interest expense, net of investment income	(86,676		)	(1,462		)	—			—			(88,138		)
	Income (loss) before income taxes	(90,157		)	380,273			20,486			—			310,602
	Income tax (benefit) expense	(34,846		)	144,569			7,918			—			117,641
	Income (loss) from continuing operations	(55,311		)	235,704			12,568			—			192,961
	Loss from discontinued operations	—			(1,245		)	(41,140		)	—			(42,385		)
	Equity of net income of subsidiaries	205,887			—			—			(205,887		)	—
	Net income	$	150,576		$	234,459		$	(28,572	)	$	(205,887	)	$	150,576
	Comprehensive income	$	151,182		$	234,459		$	(28,572	)	$	(205,887	)	$	151,182
2013:00:00
Net sales	$	—		$	4,383,420		$	93,809		$	—		$	4,477,229
Cost of sales	—			3,362,356			53,683			—			3,416,039
Gross profit	—			1,021,064			40,126			—			1,061,190
Selling, general and administrative expenses	3,696			547,264			14,316			—			565,276
Provision for doubtful accounts	—			73,671			1,442			—			75,113
Settlement, litigation and other related charges	—			169,615			—			—			169,615
Other charges	—			89,635			7,271			—			96,906
Operating income (loss)	(3,696		)	140,879			17,097			—			154,280
Interest expense, net of investment income	(92,757		)	(890		)	(364		)	—			(94,011		)
Income (loss) before income taxes	(96,453		)	139,989			16,733			—			60,269
Income tax (benefit) expense	(37,395		)	62,093			9,306			—			34,004
Income (loss) from continuing operations	(59,058		)	77,896			7,427			—			26,265
Income (loss) from discontinued operations	—			(9,115		)	23,114			—			13,999
Equity of net income of subsidiaries	99,322			—			—			(99,322		)	—
Net income	$	40,264		$	68,781		$	30,541		$	(99,322	)	$	40,264
Comprehensive loss	$	40,170		$	68,781		$	30,541		$	(99,322	)	$	40,170
Note 9 - Guarantor Subsidiaries (Continued)
Condensed Consolidating Balance Sheets
(in thousands)
As of September 30, 2014:	Parent			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Consolidating/Eliminating Adjustments			Omnicare, Inc. and Subsidiaries
ASSETS
Cash and cash equivalents	$	248,786		$	26,183		$	11,974		$	—		$	286,943
Accounts receivable, net (including intercompany)	—			648,877			94,673			(92,326		)	651,224
Inventories	—			486,761			7,802			—			494,563
Deferred income tax benefits, net-current	—			56,135			374			(425		)	56,084
Other current assets	30,506			257,138			27,521			—			315,165
Current assets of discontinued operations	—			—			—			—			—
Total current assets	279,292			1,475,094			142,344			(92,751		)	1,803,979
Properties and equipment, net	—			325,405			5,196			—			330,601
Goodwill	—			4,031,878			28,805			—			4,060,683
Identifiable intangible assets, net	—			104,884			1,541			—			106,425
Other noncurrent assets	38,039			57,571			39			—			95,649
Noncurrent assets of discontinued operations	—			—			—			—			—
Investment in subsidiaries	4,952,869			—			—			(4,952,869		)	—
Total assets	$	5,270,200		$	5,994,832		$	177,925		$	(5,045,620	)	$	6,397,337
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities (including intercompany)	$	30,230		$	472,964		$	32,138		$	(92,326	)	$	443,006
Current portion of long-term debt	495,713			—			—			—			495,713
Current liabilities of discontinued operations	—			—			—			—			—
Long-term debt, notes and convertible debentures	1,402,712			8,758			—			—			1,411,470
Deferred income tax liabilities	377,955			645,327			—			(425		)	1,022,857
Other noncurrent liabilities	—			58,891			1,810			—			60,701
Noncurrent liabilities of discontinued operations	—			—			—			—			—
Convertible debt	308,787			—			—			—			308,787
Stockholders’ equity	2,654,803			4,808,892			143,977			(4,952,869		)	2,654,803
Total liabilities and stockholders’ equity	$	5,270,200		$	5,994,832		$	177,925		$	(5,045,620	)	$	6,397,337
As of December 31, 2013:
ASSETS
Cash and cash equivalents	$	275,910		$	68,050		$	12,041		$	—		$	356,001
Accounts receivable, net (including intercompany)	—			693,729			315,323			(313,368		)	695,684
Inventories	—			505,567			6,851			—			512,418
Deferred income tax benefits, net-current	—			135,148			—			(54		)	135,094
Other current assets	1,989			242,166			21,381			—			265,536
Current assets of discontinued operations	—			12,305			37,690			—			49,995
Total current assets	277,899			1,656,965			393,286			(313,422		)	2,014,728
Properties and equipment, net	—			301,200			4,688			—			305,888
Goodwill	—			4,028,651			28,805			—			4,057,456
Identifiable intangible assets, net	—			127,798			2,176			—			129,974
Other noncurrent assets	41,825			54,834			63			—			96,722
Noncurrent assets of discontinued operations	—			3,762			83,316			—			87,078
Investment in subsidiaries	5,131,280			—			—			(5,131,280		)	—
Total assets	$	5,451,004		$	6,173,210		$	512,334		$	(5,444,702	)	$	6,691,846
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities (including intercompany)	$	83,028		$	793,461		$	23,986		$	(313,368	)	$	587,107
Current portion of long-term debt	527,204			—			—			—			527,204
Current liabilities of discontinued operations	—			1,894			16,952			—			18,846
Long-term debt, notes and convertible debentures	1,405,628			13,191			—			—			1,418,819
Deferred income tax liabilities	363,240			635,640			13,907			(54		)	1,012,733
Other noncurrent liabilities	—			52,072			1,763			—			53,835
Noncurrent liabilities of discontinued operations	—			176			1,222			—			1,398
Convertible debt	331,101			—			—			—			331,101
Stockholders’ equity	2,740,803			4,676,776			454,504			(5,131,280		)	2,740,803
Total liabilities and stockholders’ equity	$	5,451,004		$	6,173,210		$	512,334		$	(5,444,702	)	$	6,691,846
Note 9 - Guarantor Subsidiaries (Continued)
Condensed Consolidating Statements of Cash Flows
(in thousands)
	For the nine months ended September 30,
2014:00:00	Parent			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Omnicare, Inc. and Subsidiaries
Cash flows from operating activities:
Net cash flows (used in) from operating activities	$	(68,865	)	$	425,119		$	(837	)	$	355,417
Cash flows from investing activities:
Divestiture of businesses, net	—			71,194			—			71,194
Capital expenditures	—			(67,217		)	(654		)	(67,871		)
Other	—			(881		)	—			(881		)
Net cash flows from (used in) investing activities	—			3,096			(654		)	2,442
Cash flows from financing activities:
Payments on terms loans	(15,938		)	—			—			(15,938		)
Payments on long-term borrowings and obligations	(176,983		)	—			—			(176,983		)
Decrease in cash overdraft balance	(10,036		)	(9,750		)	—			(19,786		)
Payments for Omnicare common stock repurchase	(160,438		)	—			—			(160,438		)
Dividends paid	(58,419		)	—			—			(58,419		)
Other	463,555			(458,908		)	—			4,647
Net cash flows from (used in) financing activities	41,741			(468,658		)	—			(426,917		)
Net increase (decrease) in cash and cash equivalents	(27,124		)	(40,443		)	(1,491		)	(69,058		)
Increase (decrease) from discontinued operations	—			1,424			(1,424		)	—
Net increase (decrease) from continuing operations	(27,124		)	(41,867		)	(67		)	(69,058		)
Cash and cash equivalents at beginning of period	275,910			68,050			12,041			356,001
Cash and cash equivalents at end of period	$	248,786		$	26,183		$	11,974		$	286,943
2013:00:00
Cash flows from operating activities:
Net cash flows (used in) from operating activities	$	(42,519	)	$	507,984		$	(10,800	)	$	454,665
Cash flows from investing activities:
Acquisition of businesses, net of cash received	—			(3,798		)	—			(3,798		)
Divestiture of business, net	—			675			10,408			11,083
Capital expenditures	—			(71,984		)	(1,295		)	(73,279		)
Other	(227		)	(180		)	—			(407		)
Net cash flows used in investing activities	(227		)	(75,287		)	9,113			(66,401		)
Cash flows from financing activities:
Payments on term loans	(15,938		)	—			—			(15,938		)
Payments on long-term borrowings and obligations	(190,403		)	—			—			(190,403		)
Fees paid for financing activities	(4,851		)	—			—			(4,851		)
Decrease in cash overdraft balance	(10,232		)	(1,258		)	—			(11,490		)
Payments for Omnicare common stock repurchases	(91,259		)	—			—			(91,259		)
Dividends paid	(43,011		)	—			—			(43,011		)
Other	442,769			(422,607		)	—			20,162
Net cash flows from (used in) financing activities	87,075			(423,865		)	—			(336,790		)
Net increase in cash and cash equivalents	44,329			8,832			(1,687		)	51,474
Decrease from discontinued operations	—			—			(2,169		)	(2,169		)
Net increase (decrease) from continuing operations	44,329			8,832			482			53,643
Cash and cash equivalents at beginning of period	383,674			49,108			11,838			444,620
Cash and cash equivalents at end of period	$	428,003		$	57,940		$	12,320		$	498,263
Note 9 - Guarantor Subsidiaries (Continued)
The Company’s 3.25% Convertible Senior Debentures due 2035 (with optional redemption by Omnicare on or after, or an optional repurchase right of holders on, December 15, 2015, at par) are fully and unconditionally guaranteed, subject to certain customary release provisions, on an unsecured basis by Omnicare Purchasing Company, LP, a 100% owned subsidiary of the Company (the “Guarantor Subsidiary”). The following condensed consolidating unaudited financial data illustrates the composition of Omnicare, Inc. (“Parent”), the Guarantor Subsidiary and the Non-Guarantor Subsidiaries as of September 30, 2014 and December 31, 2013 for the balance sheets, as well as the three and nine months ended September 30, 2014 and 2013 for the statements of comprehensive income (loss) and the statements of cash flows. Management believes separate complete financial statements of the Guarantor Subsidiary would not provide information that would be necessary for evaluating the sufficiency of the Guarantor Subsidiary, and thus are not presented. The Guarantor Subsidiary does not have any material net cash flows in the condensed consolidating statements of cash flows. The equity method has been used with respect to the Parent company’s investment in subsidiaries. No consolidating/eliminating adjustments column is presented for the condensed consolidating statements of cash flows since there were no significant consolidating/eliminating adjustment amounts during the periods presented.
Summary Consolidating
Statements of Comprehensive Income (Loss)
(in thousands)
	For the three months ended September 30,
2014:00:00	Parent			Guarantor Subsidiary			Non-Guarantor Subsidiaries			Consolidating /			Omnicare, Inc. and Subsidiaries
										Eliminating Adjustments
Net sales	$	—		$	—		$	1,608,055		$	—		$	1,608,055
Cost of sales	—			—			1,256,595			—			1,256,595
Gross profit	—			—			351,460			—			351,460
Selling, general and administrative expenses	1,053			430			177,457			—			178,940
Provision for doubtful accounts	—			—			19,911			—			19,911
Settlement, litigation and other related charges	—			—			12,868			—			12,868
Other charges	—			—			3,999			—			3,999
Operating income (loss)	(1,053		)	(430		)	137,225			—			135,742
Interest expense, net of investment income	(28,456		)	—			(261		)	—			(28,717		)
Income (loss) before income taxes	(29,509		)	(430		)	136,964			—			107,025
Income tax (benefit) expense	(11,503		)	(168		)	50,619			—			38,948
Income (loss) from continuing operations	(18,006		)	(262		)	86,345			—			68,077
Loss from discontinued operations	—			—			(3,246		)	—			(3,246		)
Equity of net income of subsidiaries	82,837			—			—			(82,837		)	—
Net income (loss)	$	64,831		$	(262	)	$	83,099		$	(82,837	)	$	64,831
Comprehensive income (loss)	$	65,170		$	(262	)	$	83,099		$	(82,837	)	$	65,170
2013:00:00
Net sales	$	—		$	—		$	1,515,168		$	—		$	1,515,168
Cost of sales	—			—			1,163,197			—			1,163,197
Gross profit	—			—			351,971			—			351,971
Selling, general and administrative expenses	1,504			417			180,747			—			182,668
Provision for doubtful accounts	—			—			24,963			—			24,963
Settlement, litigation and other related charges	—			—			143,484			—			143,484
Other charges	—			—			61,632			—			61,632
Operating loss	(1,504		)	(417		)	(58,855		)	—			(60,776		)
Interest expense, net of investment income	(34,583		)	—			(342		)	—			(34,925		)
Loss before income taxes	(36,087		)	(417		)	(59,197		)	—			(95,701		)
Income tax benefit	(14,190		)	(164		)	(11,996		)	—			(26,350		)
Loss from continuing operations	(21,897		)	(253		)	(47,201		)	—			(69,351		)
Income from discontinued operations	—			—			3,042			—			3,042
Equity of net income of subsidiaries	(44,412		)	—			—			44,412			—
Net income (loss)	$	(66,309	)	$	(253	)	$	(44,159	)	$	44,412		$	(66,309	)
Comprehensive income (loss)	$	(66,305	)	$	(253	)	$	(44,159	)	$	44,412		$	(66,305	)
Note 9 - Guarantor Subsidiaries (Continued)
Summary Consolidating
Statements of Comprehensive Income (Loss)
(in thousands)
	For the nine months ended September 30,
2014:00:00	Parent			Guarantor Subsidiary			Non-Guarantor Subsidiaries			Consolidating /			Omnicare, Inc. and Subsidiaries
										Eliminating Adjustments
Net sales	$	—		$	—		$	4,789,677		$	—		$	4,789,677
Cost of sales	—			—			3,725,533			—			3,725,533
Gross profit	—			—			1,064,144			—			1,064,144
Selling, general and administrative expenses	3,481			1,309			545,026			—			549,816
Provision for doubtful accounts	—			—			62,562			—			62,562
Settlement, litigation and other related charges	—			—			27,467			—			27,467
Other charges	—			—			25,559			—			25,559
Operating income (loss)	(3,481		)	(1,309		)	403,530			—			398,740
Interest expense, net of investment income	(86,676		)	—			(1,462		)	—			(88,138		)
Income (loss) before income taxes	(90,157		)	(1,309		)	402,068			—			310,602
Income tax (benefit) expense	(34,846		)	(506		)	152,993			—			117,641
Income (loss) from continuing operations	(55,311		)	(803		)	249,075			—			192,961
Loss from discontinued operations	—			—			(42,385		)	—			(42,385		)
Equity of net income of subsidiaries	205,887			—			—			(205,887		)	—
Net income (loss)	$	150,576		$	(803	)	$	206,690		$	(205,887	)	$	150,576
Comprehensive income (loss)	$	151,182		$	(803	)	$	206,690		$	(205,887	)	$	151,182
2013:00:00
Net sales	$	—		$	—		$	4,477,229		$	—		$	4,477,229
Cost of sales	—			—			3,416,039			—			3,416,039
Gross profit	—			—			1,061,190			—			1,061,190
Selling, general and administrative expenses	3,696			1,233			560,347			—			565,276
Provision for doubtful accounts	—			—			75,113			—			75,113
Settlement, litigation and other related charges	—			—			169,615			—			169,615
Other charges	—			—			96,906			—			96,906
Operating income (loss)	(3,696		)	(1,233		)	159,209			—			154,280
Interest expense, net of investment income	(92,757		)	—			(1,254		)	—			(94,011		)
Income (loss) before income taxes	(96,453		)	(1,233		)	157,955			—			60,269
Income tax (benefit) expense	(37,395		)	(478		)	71,877			—			34,004
Income (loss) from continuing operations	(59,058		)	(755		)	86,078			—			26,265
Income from discontinued operations	—			—			13,999			—			13,999
Equity of net income of subsidiaries	99,322			—			—			(99,322		)	—
Net income (loss)	$	40,264		$	(755	)	$	100,077		$	(99,322	)	$	40,264
Comprehensive income (loss)	$	40,170		$	(755	)	$	100,077		$	(99,322	)	$	40,170
Note 9 - Guarantor Subsidiaries (Continued)
Condensed Consolidating Balance Sheets
(in thousands)
As of September 30, 2014:	Parent			Guarantor Subsidiary			Non-Guarantor Subsidiaries			Consolidating/Eliminating Adjustments			Omnicare, Inc. and Subsidiaries
ASSETS
Cash and cash equivalents	$	248,786		$	—		$	38,157		$	—		$	286,943
Accounts receivable, net (including intercompany)	—			192			651,224			(192		)	651,224
Inventories	—			—			494,563			—			494,563
Deferred income tax benefits, net-current	—			—			56,084			—			56,084
Other current assets	30,506			—			284,659			—			315,165
Current assets of discontinued operations	—			—			—			—			—
Total current assets	279,292			192			1,524,687			(192		)	1,803,979
Properties and equipment, net	—			13			330,588			—			330,601
Goodwill	—			—			4,060,683			—			4,060,683
Identifiable intangible assets, net	—			—			106,425			—			106,425
Other noncurrent assets	38,039			19			57,591			—			95,649
Noncurrent assets of discontinued operations	—			—			—			—			—
Investment in subsidiaries	4,952,869			—			—			(4,952,869		)	—
Total assets	$	5,270,200		$	224		$	6,079,974		$	(4,953,061	)	$	6,397,337
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities (including intercompany)	$	30,230		$	—		$	412,968		$	(192	)	$	443,006
Current portion of long-term debt	495,713			—			—			—			495,713
Current liabilities of discontinued operations	—			—			—			—			—
Long-term debt, notes and convertible debentures	1,402,712			—			8,758			—			1,411,470
Deferred income tax liabilities	377,955			—			644,902			—			1,022,857
Other noncurrent liabilities	—			—			60,701			—			60,701
Noncurrent liabilities of discontinued operations	—			—			—			—			—
Convertible debt	308,787			—			—			—			308,787
Stockholders’ equity	2,654,803			224			4,952,645			(4,952,869		)	2,654,803
Total liabilities and stockholders’ equity	$	5,270,200		$	224		$	6,079,974		$	(4,953,061	)	$	6,397,337
As of December 31, 2013:
ASSETS
Cash and cash equivalents	$	275,910		$	—		$	80,091		$	—		$	356,001
Accounts receivable, net (including intercompany)	—			210			695,684			(210		)	695,684
Inventories	—			—			512,418			—			512,418
Deferred income tax benefits, net-current	—			—			135,094			—			135,094
Other current assets	1,989			—			263,547			—			265,536
Current assets of discontinued operations	—			—			49,995			—			49,995
Total current assets	277,899			210			1,736,829			(210		)	2,014,728
Properties and equipment, net	—			19			305,869			—			305,888
Goodwill	—			—			4,057,456			—			4,057,456
Identifiable intangible assets, net	—			—			129,974			—			129,974
Other noncurrent assets	41,825			19			54,878			—			96,722
Noncurrent assets of discontinued operations	—			—			87,078			—			87,078
Investment in subsidiaries	5,131,280			—			—			(5,131,280		)	—
Total assets	$	5,451,004		$	248		$	6,372,084		$	(5,131,490	)	$	6,691,846
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities (including intercompany)	$	83,028		$	—		$	504,289		$	(210	)	$	587,107
Current portion of long-term debt	527,204			—			—			—			527,204
Current liabilities of discontinued operations	—			—			18,846			—			18,846
Long-term debt, notes and convertible debentures	1,405,628			—			13,191			—			1,418,819
Deferred income tax liabilities	363,240			—			649,493			—			1,012,733
Other noncurrent liabilities	—			—			53,835			—			53,835
Noncurrent liabilities of discontinued operations	—			—			1,398			—			1,398
Convertible debt	331,101			—			—			—			331,101
Stockholders’ equity	2,740,803			248			5,131,032			(5,131,280		)	2,740,803
Total liabilities and stockholders’ equity	$	5,451,004		$	248		$	6,372,084		$	(5,131,490	)	$	6,691,846
Note 9 - Guarantor Subsidiaries (Continued)
Condensed Consolidating Statements of Cash Flows - Unaudited
(in thousands)
	For the nine months ended September 30,
2014:00:00	Parent			Guarantor Subsidiary			Non-Guarantor Subsidiaries			Omnicare, Inc. and Subsidiaries
Cash flows from operating activities:
Net cash flows (used in) from operating activities	$	(68,865	)	$	—		$	424,282		$	355,417
Cash flows from investing activities:
Disposition of businesses	—			—			71,194			71,194
Capital expenditures	—			—			(67,871		)	(67,871		)
Other	—			—			(881		)	(881		)
Net cash flows from investing activities	—			—			2,442			2,442
Cash flows from financing activities:
Payments on terms loans	(15,938		)	—			—			(15,938		)
Payments on long-term borrowings and obligations	(176,983		)	—			—			(176,983		)
Decrease in cash overdraft balance	(10,036		)	—			(9,750		)	(19,786		)
Payments for Omnicare common stock repurchase	(160,438		)	—			—			(160,438		)
Dividends paid	(58,419		)	—			—			(58,419		)
Other	463,555			—			(458,908		)	4,647
Net cash flows from (used in) financing activities	41,741			—			(468,658		)	(426,917		)
Net increase (decrease) in cash and cash equivalents	(27,124		)	—			(41,934		)	(69,058		)
Less increase in cash and cash equivalents of discontinued operations	—			—			—			—
Increase (decrease) in cash and cash equivalents of continuing operations	(27,124		)	—			(41,934		)	(69,058		)
Cash and cash equivalents at beginning of period	275,910			—			80,091			356,001
Cash and cash equivalents at end of period	$	248,786		$	—		$	38,157		$	286,943
2013:00:00
Cash flows from operating activities:
Net cash flows (used in) from operating activities	$	(42,519	)	$	—		$	497,184		$	454,665
Cash flows from investing activities:
Acquisition of businesses, net of cash received	—			—			(3,798		)	(3,798		)
Divestiture of business, net	—			—			11,083			11,083
Capital expenditures	—			—			(73,279		)	(73,279		)
Other	(227		)	—			(180		)	(407		)
Net cash flows used in investing activities	(227		)	—			(66,174		)	(66,401		)
Cash flows from financing activities:
Payments on term loans	(15,938		)	—			—			(15,938		)
Payments on long-term borrowings and obligations	(190,403		)	—			—			(190,403		)
Fees paid for financing activities	(4,851		)	—			—			(4,851		)
Decrease in cash overdraft balance	(10,232		)	—			(1,258		)	(11,490		)
Payments for Omnicare common stock repurchases	(91,259		)	—			—			(91,259		)
Dividends paid	(43,011		)	—			—			(43,011		)
Other	442,769			—			(422,607		)	20,162
Net cash flows from (used in) financing activities	87,075			—			(423,865		)	(336,790		)
Net increase in cash and cash equivalents	44,329			—			7,145			51,474
Less decrease in cash and cash equivalents of discontinued operations	—			—			(2,169		)	(2,169		)
Increase (decrease) in cash and cash equivalents of continuing operations	44,329			—			9,314			53,643
Cash and cash equivalents at beginning of period	383,674			—			60,946			444,620
Cash and cash equivalents at end of period	$	428,003		$	—		$	70,260		$	498,263

Significant_Accounting_Policie1

Significant Accounting Policies Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2014
Significant Accounting Policies [Abstract]	'
Option Indexed to Issuer's Equity, Description [Text Block]	'
	Capped Call
	On April 2, 2012, the Company entered into capped call transactions with a counterparty, paying $48 million for the purchase of the capped calls, which was recorded as additional paid-in capital. The capped call transactions are intended to reduce potential economic dilution upon conversion of the Company’s 3.75% Convertible Senior Subordinated Notes due 2042. The capped calls settle in tranches through March 2016, one of which settled in the first quarter of 2014. The adjusted strike price for the capped calls ranged from $40.96 to $41.05 and the adjusted cap price for the tranche settled in 2014 ranged from $56.75 to $56.88; the strike and cap prices adjust for the Company’s dividend payments. The Company received approximately 0.6 million net shares upon settlement with a value of approximately $38 million.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	'
	Stock-Based Compensation
	Stock-based compensation expense recognized in the Consolidated Statement of Comprehensive Income (Loss) for stock options, restricted stock units, performance share units and stock awards totaled approximately $5 million and $15 million, respectively, for the three and nine months ended September 30, 2014 and $5 million and $14 million for the three and nine months ended September 30, 2013, respectively.
Income Tax, Policy [Policy Text Block]	'
	Income Taxes
	The Company’s effective tax rate for the three and nine months ended September 30, 2014 and September 30, 2013 is different than the applicable federal statutory rate primarily as a result of the impact of state and local income taxes and additional tax benefits recognized in 2014 for prior year settlement payments, and the non-deductible portion of the settlement payments made related to the Gale and Silver complaints (each as described in “Note 7 - Commitments and Contingencies”).
Trade and Other Accounts Receivable, Policy [Policy Text Block]	'
	Accounts Receivable
	The following table is an aging of the Company’s gross accounts receivable (net of allowances for contractual adjustments), aged based on payment terms and categorized based on the three primary types of payors (in thousands):
	September 30, 2014	Current and 0-180 Days Past Due		181 Days and Over Past Due		Total
	Medicare (Part D and Part B), Medicaid and Third-Party payors	$	201,382	$	47,497	$	248,879
	Facility payors	306,681		122,378		429,059
	Private Pay payors	76,953		91,013		167,966
	Total gross accounts receivable	$	585,016	$	260,888	$	845,904
	December 31, 2013
	Medicare (Part D and Part B), Medicaid and Third-Party payors	$	195,544	$	67,791	$	263,335
	Facility payors	328,444		146,751		475,195
	Private Pay payors	75,655		84,101		159,756
	Total gross accounts receivable	$	599,643	$	298,643	$	898,286
Common Stock Repurchase Agreement [Policy Text Block]	'
	Common Stock Repurchase Program
	In the nine months ended September 30, 2014, the Company repurchased approximately 2.7 million shares of its common stock at an aggregate cost of approximately $160 million under share repurchase programs authorized by its Board of Directors. Through September 30, 2014, the Company has repurchased an aggregate of approximately 27 million shares of its common stock at an aggregate cost of approximately $1 billion under the share repurchase programs. During the nine months ended September 30, 2013, the Company repurchased approximately 2.5 million shares of its common stock at an aggregate cash outlay of approximately $91 million through authorized share repurchase programs. The cash expenditure in the nine months ended September 30, 2013 includes the impact of the equity forward contract components of the Company’s two previously disclosed accelerated share repurchase agreements. As of September 30, 2014, the Company had authority to repurchase approximately $340 million of additional shares under the share repurchase programs through December 31, 2015.

Significant_Accounting_Policie2

Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	'
	The Company’s financial instruments, measured at fair value on a recurring basis, were as follows (in thousands):
							Based on
			Fair Value				Quoted Prices in Active Markets				Other Observable Inputs			Unobservable Inputs
							(Level 1)				(Level 2)			(Level 3)
	September 30, 2014
	Bond portfolio		$	25,216			$	—			$	25,216		$	—
	7.75% interest rate swap agreements - fair value hedge		18,041				—				18,041			—
	Derivatives		—				—				—			—
	Total		$	43,257			$	—			$	43,257		$	—
	December 31, 2013
	Bond portfolio		$	25,140			$	—			$	25,140		$	—
	7.75% interest rate swap agreements - fair value hedge		18,671				—				18,671			—
	Derivatives		—				—				—			—
	Total		$	43,811			$	—			$	43,811		$	—
Accounts Receivable [Table Text Block]	'
	The following table is an aging of the Company’s gross accounts receivable (net of allowances for contractual adjustments), aged based on payment terms and categorized based on the three primary types of payors (in thousands):
	September 30, 2014		Current and 0-180 Days Past Due				181 Days and Over Past Due				Total
	Medicare (Part D and Part B), Medicaid and Third-Party payors		$	201,382			$	47,497			$	248,879
	Facility payors		306,681				122,378				429,059
	Private Pay payors		76,953				91,013				167,966
	Total gross accounts receivable		$	585,016			$	260,888			$	845,904
	December 31, 2013
	Medicare (Part D and Part B), Medicaid and Third-Party payors		$	195,544			$	67,791			$	263,335
	Facility payors		328,444				146,751				475,195
	Private Pay payors		75,655				84,101				159,756
	Total gross accounts receivable		$	599,643			$	298,643			$	898,286
Accumulated other comprehensive income(loss) [Table Text Block]	'
	The following table is a summary of the Company’s accumulated other comprehensive income (loss) (“AOCI”) (in thousands):
			September 30,				December 31, 2013
			2014
	Unrealized loss on fair value of investments		$	(571	)		$	(702	)
	Pension and post-employment benefits		(1,364		)		(1,839		)
	Total accumulated other comprehensive loss, net		$	(1,935	)		$	(2,541	)
Schedule of Other Nonoperating Expense, by Component [Table Text Block]	'
	Other Charges
	Other charges (on a pre-tax basis) consist of the following (in thousands):
		Three months ended								Nine months ended
		September 30,								September 30,
		2014				2013				2014			2013
	Debt related costs	$	72			$	50,868			$	7,832		$	50,868
	Disposition of businesses	285				10,116				805			38,902
	Separation and other costs	3,642				648				16,922			4,836
	Acquisition and other related costs	—				—				—			2,300
	Total - other charges	$	3,999			$	61,632			$	25,559		$	96,906
Offsetting Assets [Table Text Block]	'
	The Company has interest rate swap agreements (the “Interest Rate Swap Agreements”) with multiple counterparties with respect to all $400 million aggregate principle amount outstanding of its 7.75% Senior Subordinated Notes due 2020 (the “2020 Notes”). The following table presents the effect of netting arrangements on the Company’s recognized assets and liabilities in connection with the Interest Rate Swap Agreements as of September 30, 2014 and December 31, 2013 (in thousands):
											Gross Amounts not offset in the statement of financial position
	Interest Rate Swaps as of:	Gross amount of recognized assets (liabilities)			Gross amount offset in the statement of financial position			Net amount of assets (liabilities) presented in the statement of financial position			Financial instruments		Cash collateral received			Net amount
	30-Sep-14
	Swap A	$	9,130		$	—		$	9,130		$	—	$	—		$	9,130
	Swap B	8,911			—			8,911			—		—			8,911
		$	18,041		$	—		$	18,041		$	—	$	—		$	18,041
	December 31, 2013
	Swap A	$	9,408		$	—		$	9,408		$	—	$	—		$	9,408
	Swap B	9,263			—			9,263			—		—			9,263
		$	18,671		$	—		$	18,671		$	—	$	—		$	18,671

Discontinued_operations_Tables

Discontinued operations (Tables)	9 Months Ended
	Sep. 30, 2014
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]	'
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]	'
	Selected financial information related to the discontinued operations follows (in thousands):
		Three months ended September 30,						Nine months ended September 30,
		2014			2013			2014			2013
	Net Sales
	Hospice	$	25,163		$	52,774		$	123,071		$	158,240
	Retail	—			13,059			10,698			40,432
	Net sales - total discontinued	25,163			65,833			133,769			198,672
	Income (loss) from operations, pretax
	Hospice	(2,566		)	5,155			548			23,149
	Retail	104			(234		)	(1,546		)	(498		)
	Income (loss) from operations - total discontinued, pretax	(2,462		)	4,921			(998		)	22,651
	Income tax (benefit) expense
	Hospice	664			1,972			2,344			8,856
	Retail	120			(93		)	(761		)	(204		)
	Income tax (benefit) expense - total discontinued	784			1,879			1,583			8,652
	Income (loss) from operations of discontinued operations
	Hospice	(3,230		)	3,183			(1,796		)	14,293
	Retail	(16		)	(141		)	(785		)	(294		)
	Income (loss) from operations - total discontinued, after tax	(3,246		)	3,042			(2,581		)	13,999
	Impairment loss
	Hospice	—			—			39,804			—
	Retail	—			—			—			—
	Impairment loss on discontinued operations - total	—			—			39,804			$	—
	Income (loss) from discontinued operations
	Hospice	(3,230		)	3,183			(41,600		)	14,293
	Retail	(16		)	(141		)	(785		)	(294		)
	(Loss) income from discontinued operations - total	$	(3,246	)	$	3,042		$	(42,385	)	$	13,999

Goodwill_and_Other_Intangible_1

Goodwill and Other Intangible Assets Goodwill changes (Tables)	9 Months Ended
	Sep. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule of Goodwill [Table Text Block]	'
		Long-Term Care Group			Specialty Care Group		Total
	Goodwill balance as of December 31, 2013	$	3,567,019		$	490,437	$	4,057,456
	Disposition of business	(41		)	—		(41		)
	Other	3,268			—		3,268
	Goodwill balance as of September 30, 2014	$	3,570,246		$	490,437	$	4,060,683

Debt_Tables

Debt (Tables)	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
Contingent Interest on Debt [Table Text Block]	'
	The contingent interest is accrued at the respective rate applied to the average trading price of the Trust PIERS for the five trading days ending on the respective date as outlined in the table below:
	Accrual Period			Contingent Interest Rate	Trading price period end date		Cash interest paid per $50 stated liquidation amount of Trust PIERS				Payment Date
	Start Date	End Date
	December 15, 2013	March 14, 2014		0.13%	December 12, 2013		$	0.09			March 17, 2014
	March 15, 2014	June 14, 2014		0.13%	March 13, 2014		$	0.09			June 16, 2014
	June 15, 2014	September 15, 2014		0.13%	June 12, 2014		$	0.09			September 15, 2014
	September 15, 2014	December 14, 2014		0.13%	September 12, 2014		$	0.1			December 15, 2014
Fair Value, by Balance Sheet Grouping [Table Text Block]	'
	The fair value of the Company’s fixed-rate debt facilities, excluding the Interest Rate Swap Agreements, is based on quoted market prices (Level II) and is summarized as follows (in thousands):
	Fair Value of Financial Instruments
		September 30, 2014							December 31, 2013
	Financial Instrument	Book Value			Market Value				Book Value			Market Value
	7.75% senior subordinated notes, due 2020	$	400,000		$	421,000			$	400,000		$	435,800
	3.75% convertible senior subordinated notes, due 2025
	Carrying value	53,801			—				87,310			—
	Unamortized debt discount	26,178			—				45,098			—
	Principal amount	79,979			180,800				132,408			306,500
	4.00% junior subordinated convertible debentures, due 2033
	Carrying value	188,124			—				186,136			—
	Unamortized debt discount	118,998			—				121,017			—
	Principal amount	307,122			468,300				307,153			455,900
	3.25% convertible senior debentures, due 2035
	Carrying value	405,419			—				393,126			—
	Unamortized debt discount	22,081			—				34,374			—
	Principal amount	427,500			450,000				427,500			457,400
	3.75% convertible senior subordinated notes, due 2042
	Carrying value	226,389			—				225,014			—
	Unamortized debt discount	163,611			—				164,986			—
	Principal amount	390,000			608,000				390,000			592,800
	3.50% convertible senior subordinated notes, due 2044
	Carrying value	218,003			—				216,643			—
	Unamortized debt discount	206,247			—				207,607			—
	Principal amount	424,250			469,600				424,250			428,500
Summary of Debt	'
	(in thousands):
		September 30,			December 31,
		2014			2013
	Revolving credit facility, due 2017	$	—		$	—
	Senior term loan, due 2017	382,500			398,438
	7.75% senior subordinated notes, due 2020	400,000			400,000
	3.75% convertible senior subordinated notes, due 2025	79,979			132,408
	4.00% junior subordinated convertible debentures, due 2033	307,122			307,153
	3.25% convertible senior debentures, due 2035	427,500			427,500
	3.75% convertible senior subordinated notes, due 2042	390,000			390,000
	3.50% convertible senior subordinated notes, due 2044	424,250			424,250
	Capitalized lease and other debt obligations	14,906			20,685
	Subtotal	2,426,257			2,500,434
	Add interest rate swap agreements	18,041			18,671
	(Subtract) unamortized debt discount	(537,115		)	(573,082		)
	(Subtract) current portion of debt	(495,713		)	(527,204		)
	Total long-term debt, net	$	1,411,470		$	1,418,819
Convertible debt and related equity	'
	Information relating to the Company’s convertible securities at September 30, 2014 is in the following table:
	Convertible Debt	Carrying Value of Equity Component (in thousands)			Remaining Amortization Period		Effective Interest Rate
	3.75% convertible senior subordinated notes, due 2025	$	6,913		11.25		8.25	%
	4.00% junior subordinated convertible debentures, due 2033	$	118,348		18.75		8.01	%
	3.25% convertible senior debentures, due 2035	$	245,433		1.25		7.63	%
	3.75% convertible senior subordinated notes, due 2042	$	167,941		27.5		7.3	%
	3.50% convertible senior subordinated notes, due 2044	$	208,200		29.4		7.7	%

Earnings_Loss_Per_Share_Data_T

Earnings (Loss) Per Share Data (Tables)	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Weighted Average Stock Price to include additional shares in diluted share calculation [Table Text Block]	'
	The Company is required to include additional shares in its diluted shares outstanding calculation based on the treasury stock method when the average market price of a share of Omnicare stock on the New York Stock Exchange for the applicable period exceeds the following amounts:
	Convertible Debt	Price
	3.75% convertible senior subordinated notes, due 2025	$	26.84
	4.00% junior subordinated convertible debentures, due 2033	$	40.82
	3.25% convertible senior debentures, due 2035	$	77.88
	3.75% convertible senior subordinated notes, due 2042	$	41.05
	3.50% convertible senior subordinated notes, due 2044	$	70
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	'
	The following is a reconciliation of the basic and diluted earnings per share (“EPS”) computations for both the numerator and denominator (in thousands, except per share data):
		Three months ended September 30,							Nine months ended September 30,
	2014:00:00	Income (Numerator)			Common Shares(Denominator)	Per Common			Income (Numerator)			Common Shares(Denominator)	Per Common
						Share Amounts							Share Amounts
	Basic EPS
	Income from continuing operations	$	68,077			$	0.7		$	192,961			$	1.98
	Loss from discontinued operations	(3,246		)		(0.03		)	(42,385		)		(0.43		)
	Net income	$	64,831		97,019	$	0.67		$	150,576		97,521	$	1.54
	Effect of Dilutive Securities
	Convertible securities	66			7,945				198			8,283
	Stock options, units and awards	—			584				—			646
	Diluted EPS
	Income from continuing operations plus assumed conversions	$	68,143			$	0.65		$	193,159			$	1.81
	Loss from discontinued operations	(3,246		)		(0.03		)	(42,385		)		(0.40		)
	Net income plus assumed conversions	$	64,897		105,548	$	0.61		$	150,774		106,450	$	1.42
		Three months ended September 30,							Nine months ended September 30,
	2013:00:00	Income (Numerator)			Common Shares(Denominator)	Per Common			Income (Numerator)			Common Shares(Denominator)	Per Common
						Share Amounts							Share Amounts
	Basic EPS
	Income (loss) from continuing operations	$	(69,351	)		$	(0.68	)	$	26,265			$	0.26
	Income from discontinued operations	3,042				0.03			13,999				0.14
	Net income (loss)	$	(66,309	)	101,811	$	(0.65	)	$	40,264		102,624	$	0.39
	Effect of Dilutive Securities
	Convertible securities	—			—				212			6,360
	Stock options, warrants, units and awards	—			—				—			628
	Diluted EPS
	Income (loss) from continuing operations plus assumed conversions	$	(69,351	)		$	(0.68	)	$	26,477			$	0.24
	Income from discontinued operations	3,042				0.03			13,999				0.13
	Net income (loss) plus assumed conversions	$	(66,309	)	101,811	$	(0.65	)	$	40,476		109,612	$	0.37

Segment_Information_Segment_De

Segment Information Segment Detail (Tables)	9 Months Ended
	Sep. 30, 2014
Segment Information [Abstract]	'
Schedule of Segment Reporting Information, by Segment [Table Text Block]	'
		For the nine months ended September 30,
	2014:00:00	LTC			SCG			Corporate/Other			Consolidated
											Totals
	Net sales	$	3,565,092		$	1,224,319		$	266		$	4,789,677
	Depreciation and amortization expense	(52,258		)	(3,373		)	(44,798		)	(100,429		)
	Settlement, litigation and other related charges	(27,467		)	—			—			(27,467		)
	Other charges	(8,984		)	—			(16,575		)	(25,559		)
	Operating income (loss)	444,402			97,057			(142,719		)	398,740
	2013:00:00
	Net sales	$	3,458,772		$	1,017,127		$	1,330		$	4,477,229
	Depreciation and amortization expense	(53,801		)	(3,408		)	(42,318		)	(99,527		)
	Settlement, litigation and other related charges	(169,615		)	—			—			(169,615		)
	Other charges	(44,065		)	—			(52,841		)	(96,906		)
	Operating income (loss)	259,953			82,005			(187,678		)	154,280

Guarantor_Subsidiaries_Tables

Guarantor Subsidiaries (Tables)	9 Months Ended
	Sep. 30, 2014
Guarantor Subsidiaries [Abstract]	'
Summary Consolidating Statements of Income (Guaranteed Senior Notes Payable)	'
	Summary Consolidating
	Statements of Comprehensive Income (Loss)
	(in thousands)
		For the three months ended September 30,
	2014:00:00	Parent			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Consolidating /			Omnicare, Inc. and Subsidiaries
											Eliminating Adjustments
	Net sales	$	—		$	1,576,811		$	31,244		$	—		$	1,608,055
	Cost of sales	—			1,236,644			19,951			—			1,256,595
	Gross profit	—			340,167			11,293			—			351,460
	Selling, general and administrative expenses	1,053			172,857			5,030			—			178,940
	Provision for doubtful accounts	—			19,570			341			—			19,911
	Settlement, litigation and other related charges	—			12,868			—			—			12,868
	Other charges	—			3,999			—			—			3,999
	Operating income (loss)	(1,053		)	130,873			5,922			—			135,742
	Interest expense, net of investment income	(28,456		)	(261		)	—			—			(28,717		)
	Income (loss) before income taxes	(29,509		)	130,612			5,922			—			107,025
	Income tax (benefit) expense	(11,503		)	48,139			2,312			—			38,948
	Income (loss) from continuing operations	(18,006		)	82,473			3,610			—			68,077
	Loss from discontinued operations	—			(526		)	(2,720		)	—			(3,246		)
	Equity of net income of subsidiaries	82,837			—			—			(82,837		)	—
	Net income	$	64,831		$	81,947		$	890		$	(82,837	)	$	64,831
	Comprehensive income	$	65,170		$	81,947		$	890		$	(82,837	)	$	65,170
	2013:00:00
	Net sales	$	—		$	1,485,545		$	29,623		$	—		$	1,515,168
	Cost of sales	—			1,146,140			17,057			—			1,163,197
	Gross profit	—			339,405			12,566			—			351,971
	Selling, general and administrative expenses	1,504			176,970			4,194			—			182,668
	Provision for doubtful accounts	—			24,487			476			—			24,963
	Settlement, litigation and other related charges	—			143,484			—			—			143,484
	Other charges	—			54,361			7,271			—			61,632
	Operating income (loss)	(1,504		)	(59,897		)	625			—			(60,776		)
	Interest expense, net of investment income	(34,583		)	(344		)	2			—			(34,925		)
	Income (loss) before income taxes	(36,087		)	(60,241		)	627			—			(95,701		)
	Income tax (benefit) expense	(14,190		)	(15,270		)	3,110			—			(26,350		)
	Income (loss) from continuing operations	(21,897		)	(44,971		)	(2,483		)	—			(69,351		)
	Income (loss) from discontinued operations	—			(2,100		)	5,142			—			3,042
	Equity of net income of subsidiaries	(44,412		)	—			—			44,412			—
	Net loss	$	(66,309	)	$	(47,071	)	$	2,659		$	44,412		$	(66,309	)
	Comprehensive loss	$	(66,305	)	$	(47,071	)	$	2,659		$	44,412		$	(66,305	)
	Note 9 - Guarantor Subsidiaries (Continued)
	Summary Consolidating
	Statements of Comprehensive Income (Loss)
	(in thousands)
		For the nine months ended September 30,
	2014:00:00	Parent			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Consolidating /			Omnicare, Inc. and Subsidiaries
											Eliminating Adjustments
	Net sales	$	—		$	4,697,025		$	92,652		$	—		$	4,789,677
	Cost of sales	—			3,669,163			56,370			—			3,725,533
	Gross profit	—			1,027,862			36,282			—			1,064,144
	Selling, general and administrative expenses	3,481			531,899			14,436			—			549,816
	Provision for doubtful accounts	—			61,202			1,360			—			62,562
	Settlement, litigation and other related charges	—			27,467			—			—			27,467
	Other charges	—			25,559			—			—			25,559
	Operating income (loss)	(3,481		)	381,735			20,486			—			398,740
	Interest expense, net of investment income	(86,676		)	(1,462		)	—			—			(88,138		)
	Income (loss) before income taxes	(90,157		)	380,273			20,486			—			310,602
	Income tax (benefit) expense	(34,846		)	144,569			7,918			—			117,641
	Income (loss) from continuing operations	(55,311		)	235,704			12,568			—			192,961
	Loss from discontinued operations	—			(1,245		)	(41,140		)	—			(42,385		)
	Equity of net income of subsidiaries	205,887			—			—			(205,887		)	—
	Net income	$	150,576		$	234,459		$	(28,572	)	$	(205,887	)	$	150,576
	Comprehensive income	$	151,182		$	234,459		$	(28,572	)	$	(205,887	)	$	151,182
	2013:00:00
Net sales	$	—		$	4,383,420		$	93,809		$	—		$	4,477,229
Cost of sales	—			3,362,356			53,683			—			3,416,039
Gross profit	—			1,021,064			40,126			—			1,061,190
Selling, general and administrative expenses	3,696			547,264			14,316			—			565,276
Provision for doubtful accounts	—			73,671			1,442			—			75,113
Settlement, litigation and other related charges	—			169,615			—			—			169,615
Other charges	—			89,635			7,271			—			96,906
Operating income (loss)	(3,696		)	140,879			17,097			—			154,280
Interest expense, net of investment income	(92,757		)	(890		)	(364		)	—			(94,011		)
Income (loss) before income taxes	(96,453		)	139,989			16,733			—			60,269
Income tax (benefit) expense	(37,395		)	62,093			9,306			—			34,004
Income (loss) from continuing operations	(59,058		)	77,896			7,427			—			26,265
Income (loss) from discontinued operations	—			(9,115		)	23,114			—			13,999
Equity of net income of subsidiaries	99,322			—			—			(99,322		)	—
Net income	$	40,264		$	68,781		$	30,541		$	(99,322	)	$	40,264
Comprehensive loss	$	40,170		$	68,781		$	30,541		$	(99,322	)	$	40,170
Condensed Consolidating Balance Sheets (Guaranteed Senior Notes Payable)	'
	Condensed Consolidating Balance Sheets
	(in thousands)
	As of September 30, 2014:	Parent			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Consolidating/Eliminating Adjustments			Omnicare, Inc. and Subsidiaries
	ASSETS
	Cash and cash equivalents	$	248,786		$	26,183		$	11,974		$	—		$	286,943
	Accounts receivable, net (including intercompany)	—			648,877			94,673			(92,326		)	651,224
	Inventories	—			486,761			7,802			—			494,563
	Deferred income tax benefits, net-current	—			56,135			374			(425		)	56,084
	Other current assets	30,506			257,138			27,521			—			315,165
	Current assets of discontinued operations	—			—			—			—			—
	Total current assets	279,292			1,475,094			142,344			(92,751		)	1,803,979
	Properties and equipment, net	—			325,405			5,196			—			330,601
	Goodwill	—			4,031,878			28,805			—			4,060,683
	Identifiable intangible assets, net	—			104,884			1,541			—			106,425
	Other noncurrent assets	38,039			57,571			39			—			95,649
	Noncurrent assets of discontinued operations	—			—			—			—			—
	Investment in subsidiaries	4,952,869			—			—			(4,952,869		)	—
	Total assets	$	5,270,200		$	5,994,832		$	177,925		$	(5,045,620	)	$	6,397,337
	LIABILITIES AND STOCKHOLDERS’ EQUITY
	Current liabilities (including intercompany)	$	30,230		$	472,964		$	32,138		$	(92,326	)	$	443,006
	Current portion of long-term debt	495,713			—			—			—			495,713
	Current liabilities of discontinued operations	—			—			—			—			—
	Long-term debt, notes and convertible debentures	1,402,712			8,758			—			—			1,411,470
	Deferred income tax liabilities	377,955			645,327			—			(425		)	1,022,857
	Other noncurrent liabilities	—			58,891			1,810			—			60,701
	Noncurrent liabilities of discontinued operations	—			—			—			—			—
	Convertible debt	308,787			—			—			—			308,787
	Stockholders’ equity	2,654,803			4,808,892			143,977			(4,952,869		)	2,654,803
	Total liabilities and stockholders’ equity	$	5,270,200		$	5,994,832		$	177,925		$	(5,045,620	)	$	6,397,337
	As of December 31, 2013:
	ASSETS
	Cash and cash equivalents	$	275,910		$	68,050		$	12,041		$	—		$	356,001
	Accounts receivable, net (including intercompany)	—			693,729			315,323			(313,368		)	695,684
	Inventories	—			505,567			6,851			—			512,418
	Deferred income tax benefits, net-current	—			135,148			—			(54		)	135,094
	Other current assets	1,989			242,166			21,381			—			265,536
	Current assets of discontinued operations	—			12,305			37,690			—			49,995
	Total current assets	277,899			1,656,965			393,286			(313,422		)	2,014,728
	Properties and equipment, net	—			301,200			4,688			—			305,888
	Goodwill	—			4,028,651			28,805			—			4,057,456
	Identifiable intangible assets, net	—			127,798			2,176			—			129,974
	Other noncurrent assets	41,825			54,834			63			—			96,722
	Noncurrent assets of discontinued operations	—			3,762			83,316			—			87,078
	Investment in subsidiaries	5,131,280			—			—			(5,131,280		)	—
	Total assets	$	5,451,004		$	6,173,210		$	512,334		$	(5,444,702	)	$	6,691,846
	LIABILITIES AND STOCKHOLDERS’ EQUITY
	Current liabilities (including intercompany)	$	83,028		$	793,461		$	23,986		$	(313,368	)	$	587,107
	Current portion of long-term debt	527,204			—			—			—			527,204
	Current liabilities of discontinued operations	—			1,894			16,952			—			18,846
	Long-term debt, notes and convertible debentures	1,405,628			13,191			—			—			1,418,819
	Deferred income tax liabilities	363,240			635,640			13,907			(54		)	1,012,733
	Other noncurrent liabilities	—			52,072			1,763			—			53,835
	Noncurrent liabilities of discontinued operations	—			176			1,222			—			1,398
	Convertible debt	331,101			—			—			—			331,101
	Stockholders’ equity	2,740,803			4,676,776			454,504			(5,131,280		)	2,740,803
	Total liabilities and stockholders’ equity	$	5,451,004		$	6,173,210		$	512,334		$	(5,444,702	)	$	6,691,846
Condensed Consolidating Statements of Cash Flows (Guaranteed Senior Notes Payable)	'
	Condensed Consolidating Statements of Cash Flows
	(in thousands)
		For the nine months ended September 30,
	2014:00:00	Parent			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Omnicare, Inc. and Subsidiaries
	Cash flows from operating activities:
	Net cash flows (used in) from operating activities	$	(68,865	)	$	425,119		$	(837	)	$	355,417
	Cash flows from investing activities:
	Divestiture of businesses, net	—			71,194			—			71,194
	Capital expenditures	—			(67,217		)	(654		)	(67,871		)
	Other	—			(881		)	—			(881		)
	Net cash flows from (used in) investing activities	—			3,096			(654		)	2,442
	Cash flows from financing activities:
	Payments on terms loans	(15,938		)	—			—			(15,938		)
	Payments on long-term borrowings and obligations	(176,983		)	—			—			(176,983		)
	Decrease in cash overdraft balance	(10,036		)	(9,750		)	—			(19,786		)
	Payments for Omnicare common stock repurchase	(160,438		)	—			—			(160,438		)
	Dividends paid	(58,419		)	—			—			(58,419		)
	Other	463,555			(458,908		)	—			4,647
	Net cash flows from (used in) financing activities	41,741			(468,658		)	—			(426,917		)
	Net increase (decrease) in cash and cash equivalents	(27,124		)	(40,443		)	(1,491		)	(69,058		)
	Increase (decrease) from discontinued operations	—			1,424			(1,424		)	—
	Net increase (decrease) from continuing operations	(27,124		)	(41,867		)	(67		)	(69,058		)
	Cash and cash equivalents at beginning of period	275,910			68,050			12,041			356,001
	Cash and cash equivalents at end of period	$	248,786		$	26,183		$	11,974		$	286,943
	2013:00:00
	Cash flows from operating activities:
	Net cash flows (used in) from operating activities	$	(42,519	)	$	507,984		$	(10,800	)	$	454,665
	Cash flows from investing activities:
	Acquisition of businesses, net of cash received	—			(3,798		)	—			(3,798		)
	Divestiture of business, net	—			675			10,408			11,083
	Capital expenditures	—			(71,984		)	(1,295		)	(73,279		)
	Other	(227		)	(180		)	—			(407		)
	Net cash flows used in investing activities	(227		)	(75,287		)	9,113			(66,401		)
	Cash flows from financing activities:
	Payments on term loans	(15,938		)	—			—			(15,938		)
	Payments on long-term borrowings and obligations	(190,403		)	—			—			(190,403		)
	Fees paid for financing activities	(4,851		)	—			—			(4,851		)
	Decrease in cash overdraft balance	(10,232		)	(1,258		)	—			(11,490		)
	Payments for Omnicare common stock repurchases	(91,259		)	—			—			(91,259		)
	Dividends paid	(43,011		)	—			—			(43,011		)
	Other	442,769			(422,607		)	—			20,162
	Net cash flows from (used in) financing activities	87,075			(423,865		)	—			(336,790		)
	Net increase in cash and cash equivalents	44,329			8,832			(1,687		)	51,474
	Decrease from discontinued operations	—			—			(2,169		)	(2,169		)
	Net increase (decrease) from continuing operations	44,329			8,832			482			53,643
	Cash and cash equivalents at beginning of period	383,674			49,108			11,838			444,620
	Cash and cash equivalents at end of period	$	428,003		$	57,940		$	12,320		$	498,263
Summary Consolidating Statements of Income (Guaranteed Convertible Senior Debentures)	'
	Summary Consolidating
	Statements of Comprehensive Income (Loss)
	(in thousands)
		For the three months ended September 30,
	2014:00:00	Parent			Guarantor Subsidiary			Non-Guarantor Subsidiaries			Consolidating /			Omnicare, Inc. and Subsidiaries
											Eliminating Adjustments
	Net sales	$	—		$	—		$	1,608,055		$	—		$	1,608,055
	Cost of sales	—			—			1,256,595			—			1,256,595
	Gross profit	—			—			351,460			—			351,460
	Selling, general and administrative expenses	1,053			430			177,457			—			178,940
	Provision for doubtful accounts	—			—			19,911			—			19,911
	Settlement, litigation and other related charges	—			—			12,868			—			12,868
	Other charges	—			—			3,999			—			3,999
	Operating income (loss)	(1,053		)	(430		)	137,225			—			135,742
	Interest expense, net of investment income	(28,456		)	—			(261		)	—			(28,717		)
	Income (loss) before income taxes	(29,509		)	(430		)	136,964			—			107,025
	Income tax (benefit) expense	(11,503		)	(168		)	50,619			—			38,948
	Income (loss) from continuing operations	(18,006		)	(262		)	86,345			—			68,077
	Loss from discontinued operations	—			—			(3,246		)	—			(3,246		)
	Equity of net income of subsidiaries	82,837			—			—			(82,837		)	—
	Net income (loss)	$	64,831		$	(262	)	$	83,099		$	(82,837	)	$	64,831
	Comprehensive income (loss)	$	65,170		$	(262	)	$	83,099		$	(82,837	)	$	65,170
	2013:00:00
	Net sales	$	—		$	—		$	1,515,168		$	—		$	1,515,168
	Cost of sales	—			—			1,163,197			—			1,163,197
	Gross profit	—			—			351,971			—			351,971
	Selling, general and administrative expenses	1,504			417			180,747			—			182,668
	Provision for doubtful accounts	—			—			24,963			—			24,963
	Settlement, litigation and other related charges	—			—			143,484			—			143,484
	Other charges	—			—			61,632			—			61,632
	Operating loss	(1,504		)	(417		)	(58,855		)	—			(60,776		)
	Interest expense, net of investment income	(34,583		)	—			(342		)	—			(34,925		)
	Loss before income taxes	(36,087		)	(417		)	(59,197		)	—			(95,701		)
	Income tax benefit	(14,190		)	(164		)	(11,996		)	—			(26,350		)
	Loss from continuing operations	(21,897		)	(253		)	(47,201		)	—			(69,351		)
	Income from discontinued operations	—			—			3,042			—			3,042
	Equity of net income of subsidiaries	(44,412		)	—			—			44,412			—
	Net income (loss)	$	(66,309	)	$	(253	)	$	(44,159	)	$	44,412		$	(66,309	)
	Comprehensive income (loss)	$	(66,305	)	$	(253	)	$	(44,159	)	$	44,412		$	(66,305	)
Condensed Consolidating Balance Sheets (Guaranteed Convertible Senior Debentures)	'
	Condensed Consolidating Balance Sheets
	(in thousands)
	As of September 30, 2014:	Parent			Guarantor Subsidiary			Non-Guarantor Subsidiaries			Consolidating/Eliminating Adjustments			Omnicare, Inc. and Subsidiaries
	ASSETS
	Cash and cash equivalents	$	248,786		$	—		$	38,157		$	—		$	286,943
	Accounts receivable, net (including intercompany)	—			192			651,224			(192		)	651,224
	Inventories	—			—			494,563			—			494,563
	Deferred income tax benefits, net-current	—			—			56,084			—			56,084
	Other current assets	30,506			—			284,659			—			315,165
	Current assets of discontinued operations	—			—			—			—			—
	Total current assets	279,292			192			1,524,687			(192		)	1,803,979
	Properties and equipment, net	—			13			330,588			—			330,601
	Goodwill	—			—			4,060,683			—			4,060,683
	Identifiable intangible assets, net	—			—			106,425			—			106,425
	Other noncurrent assets	38,039			19			57,591			—			95,649
	Noncurrent assets of discontinued operations	—			—			—			—			—
	Investment in subsidiaries	4,952,869			—			—			(4,952,869		)	—
	Total assets	$	5,270,200		$	224		$	6,079,974		$	(4,953,061	)	$	6,397,337
	LIABILITIES AND STOCKHOLDERS’ EQUITY
	Current liabilities (including intercompany)	$	30,230		$	—		$	412,968		$	(192	)	$	443,006
	Current portion of long-term debt	495,713			—			—			—			495,713
	Current liabilities of discontinued operations	—			—			—			—			—
	Long-term debt, notes and convertible debentures	1,402,712			—			8,758			—			1,411,470
	Deferred income tax liabilities	377,955			—			644,902			—			1,022,857
	Other noncurrent liabilities	—			—			60,701			—			60,701
	Noncurrent liabilities of discontinued operations	—			—			—			—			—
	Convertible debt	308,787			—			—			—			308,787
	Stockholders’ equity	2,654,803			224			4,952,645			(4,952,869		)	2,654,803
	Total liabilities and stockholders’ equity	$	5,270,200		$	224		$	6,079,974		$	(4,953,061	)	$	6,397,337
	As of December 31, 2013:
	ASSETS
	Cash and cash equivalents	$	275,910		$	—		$	80,091		$	—		$	356,001
	Accounts receivable, net (including intercompany)	—			210			695,684			(210		)	695,684
	Inventories	—			—			512,418			—			512,418
	Deferred income tax benefits, net-current	—			—			135,094			—			135,094
	Other current assets	1,989			—			263,547			—			265,536
	Current assets of discontinued operations	—			—			49,995			—			49,995
	Total current assets	277,899			210			1,736,829			(210		)	2,014,728
	Properties and equipment, net	—			19			305,869			—			305,888
	Goodwill	—			—			4,057,456			—			4,057,456
	Identifiable intangible assets, net	—			—			129,974			—			129,974
	Other noncurrent assets	41,825			19			54,878			—			96,722
	Noncurrent assets of discontinued operations	—			—			87,078			—			87,078
	Investment in subsidiaries	5,131,280			—			—			(5,131,280		)	—
	Total assets	$	5,451,004		$	248		$	6,372,084		$	(5,131,490	)	$	6,691,846
	LIABILITIES AND STOCKHOLDERS’ EQUITY
	Current liabilities (including intercompany)	$	83,028		$	—		$	504,289		$	(210	)	$	587,107
	Current portion of long-term debt	527,204			—			—			—			527,204
	Current liabilities of discontinued operations	—			—			18,846			—			18,846
	Long-term debt, notes and convertible debentures	1,405,628			—			13,191			—			1,418,819
	Deferred income tax liabilities	363,240			—			649,493			—			1,012,733
	Other noncurrent liabilities	—			—			53,835			—			53,835
	Noncurrent liabilities of discontinued operations	—			—			1,398			—			1,398
	Convertible debt	331,101			—			—			—			331,101
	Stockholders’ equity	2,740,803			248			5,131,032			(5,131,280		)	2,740,803
	Total liabilities and stockholders’ equity	$	5,451,004		$	248		$	6,372,084		$	(5,131,490	)	$	6,691,846
Condensed Consolidating Statements of Cash Flows (Guaranteed Convertible Senior Debentures)	'
	Condensed Consolidating Statements of Cash Flows - Unaudited
	(in thousands)
		For the nine months ended September 30,
	2014:00:00	Parent			Guarantor Subsidiary			Non-Guarantor Subsidiaries			Omnicare, Inc. and Subsidiaries
	Cash flows from operating activities:
	Net cash flows (used in) from operating activities	$	(68,865	)	$	—		$	424,282		$	355,417
	Cash flows from investing activities:
	Disposition of businesses	—			—			71,194			71,194
	Capital expenditures	—			—			(67,871		)	(67,871		)
	Other	—			—			(881		)	(881		)
	Net cash flows from investing activities	—			—			2,442			2,442
	Cash flows from financing activities:
	Payments on terms loans	(15,938		)	—			—			(15,938		)
	Payments on long-term borrowings and obligations	(176,983		)	—			—			(176,983		)
	Decrease in cash overdraft balance	(10,036		)	—			(9,750		)	(19,786		)
	Payments for Omnicare common stock repurchase	(160,438		)	—			—			(160,438		)
	Dividends paid	(58,419		)	—			—			(58,419		)
	Other	463,555			—			(458,908		)	4,647
	Net cash flows from (used in) financing activities	41,741			—			(468,658		)	(426,917		)
	Net increase (decrease) in cash and cash equivalents	(27,124		)	—			(41,934		)	(69,058		)
	Less increase in cash and cash equivalents of discontinued operations	—			—			—			—
	Increase (decrease) in cash and cash equivalents of continuing operations	(27,124		)	—			(41,934		)	(69,058		)
	Cash and cash equivalents at beginning of period	275,910			—			80,091			356,001
	Cash and cash equivalents at end of period	$	248,786		$	—		$	38,157		$	286,943
	2013:00:00
	Cash flows from operating activities:
	Net cash flows (used in) from operating activities	$	(42,519	)	$	—		$	497,184		$	454,665
	Cash flows from investing activities:
	Acquisition of businesses, net of cash received	—			—			(3,798		)	(3,798		)
	Divestiture of business, net	—			—			11,083			11,083
	Capital expenditures	—			—			(73,279		)	(73,279		)
	Other	(227		)	—			(180		)	(407		)
	Net cash flows used in investing activities	(227		)	—			(66,174		)	(66,401		)
	Cash flows from financing activities:
	Payments on term loans	(15,938		)	—			—			(15,938		)
	Payments on long-term borrowings and obligations	(190,403		)	—			—			(190,403		)
	Fees paid for financing activities	(4,851		)	—			—			(4,851		)
	Decrease in cash overdraft balance	(10,232		)	—			(1,258		)	(11,490		)
	Payments for Omnicare common stock repurchases	(91,259		)	—			—			(91,259		)
	Dividends paid	(43,011		)	—			—			(43,011		)
	Other	442,769			—			(422,607		)	20,162
	Net cash flows from (used in) financing activities	87,075			—			(423,865		)	(336,790		)
	Net increase in cash and cash equivalents	44,329			—			7,145			51,474
	Less decrease in cash and cash equivalents of discontinued operations	—			—			(2,169		)	(2,169		)
	Increase (decrease) in cash and cash equivalents of continuing operations	44,329			—			9,314			53,643
	Cash and cash equivalents at beginning of period	383,674			—			60,946			444,620
	Cash and cash equivalents at end of period	$	428,003		$	—		$	70,260		$	498,263

Significant_Accounting_Policie3

Significant Accounting Policies Stock Based Compensation expense (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Significant Accounting Policies [Abstract]	'	'	'	'
Allocated Share-based Compensation Expense	$5	$5	$15	$14

Significant_Accounting_Policie4

Significant Accounting Policies Accounts Receivable (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Accounts Receivable, Gross, Current	$845,904	$898,286
Medicare Medicaid and Third Party Payors [Member]	'	'
Accounts Receivable, Gross, Current	248,879	263,335
Facility Payors [Member]	'	'
Accounts Receivable, Gross, Current	429,059	475,195
Private Payors [Member]	'	'
Accounts Receivable, Gross, Current	167,966	159,756
0 - 180 Days Past Due [Member]	'	'
Accounts Receivable, Gross, Current	585,016	599,643
0 - 180 Days Past Due [Member] | Medicare Medicaid and Third Party Payors [Member]	'	'
Accounts Receivable, Gross, Current	201,382	195,544
0 - 180 Days Past Due [Member] | Facility Payors [Member]	'	'
Accounts Receivable, Gross, Current	306,681	328,444
0 - 180 Days Past Due [Member] | Private Payors [Member]	'	'
Accounts Receivable, Gross, Current	76,953	75,655
181 Days and Greater Past Due [Member]	'	'
Accounts Receivable, Gross, Current	260,888	298,643
181 Days and Greater Past Due [Member] | Medicare Medicaid and Third Party Payors [Member]	'	'
Accounts Receivable, Gross, Current	47,497	67,791
181 Days and Greater Past Due [Member] | Facility Payors [Member]	'	'
Accounts Receivable, Gross, Current	122,378	146,751
181 Days and Greater Past Due [Member] | Private Payors [Member]	'	'
Accounts Receivable, Gross, Current	$91,013	$84,101

Significant_Accounting_Policie5

Significant Accounting Policies Accumulated Other Comprehensive Income (Loss) (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Unrealized (loss) gain on fair value of investments	($571)	($702)
Pension and postemployment benefits	-1,364	-1,839
Accumulated Other Comprehensive Income (Loss), Net of Tax	($1,935)	($2,541)

Significant_Accounting_Policie6

Significant Accounting Policies Fair Value (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Estimate of Fair Value, Fair Value Disclosure [Member]	'	'
Bond Portfolio at fair market value	$25,216	$25,140
Interest Rate Swap Agreement Fair Value Liability Disclosure	18,041	18,671
Derivative Financial Instruments, Liabilities, Fair Value Disclosure	0	0
Assets, Fair Value Disclosure	43,257	43,811
Fair Value, Inputs, Level 1 [Member]	'	'
Bond Portfolio at fair market value	0	0
Interest Rate Swap Agreement Fair Value Liability Disclosure	0	0
Derivative Financial Instruments, Liabilities, Fair Value Disclosure	0	0
Assets, Fair Value Disclosure	0	0
Fair Value, Inputs, Level 2 [Member]	'	'
Bond Portfolio at fair market value	25,216	25,140
Interest Rate Swap Agreement Fair Value Liability Disclosure	18,041	18,671
Derivative Financial Instruments, Liabilities, Fair Value Disclosure	0	0
Assets, Fair Value Disclosure	43,257	43,811
Fair Value, Inputs, Level 3 [Member]	'	'
Bond Portfolio at fair market value	0	0
Interest Rate Swap Agreement Fair Value Liability Disclosure	0	0
Derivative Financial Instruments, Liabilities, Fair Value Disclosure	0	0
Assets, Fair Value Disclosure	$0	$0

Significant_Accounting_Policie7

Significant Accounting Policies Offsetting Assets and Liabilities (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Deposits Paid for Securities Borrowed, at Carrying Value	$0	$0
Gross Amount of assets as Offset in Statement of Financial Position	0	0
Securities Borrowed	18,041	18,671
Financial Instruments, assets	0	0
Swap A [Member]	'	'
Deposits Paid for Securities Borrowed, at Carrying Value	0	0
Gross Amount of assets as Offset in Statement of Financial Position	0	0
Net amount of financial assets	9,130	9,408
Securities Borrowed	9,130	9,408
Financial Instruments, assets	0	0
Swap B [Member]	'	'
Deposits Paid for Securities Borrowed, at Carrying Value	0	0
Gross Amount of assets as Offset in Statement of Financial Position	0	0
Net amount of financial assets	8,911	9,263
Securities Borrowed	8,911	9,263
Financial Instruments, assets	0	0
Fair Value, Inputs, Level 2 [Member]	'	'
Interest Rate Swap Agreement Fair Value Disclosure	$18,041	$18,671

Significant_Accounting_Policie8

Significant Accounting Policies Other Charges (Credits) (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Long-term Debt, Gross	$2,426,257,000	'	$2,426,257,000	'	$2,500,434,000
Debt Related Costs	72,000	50,868,000	7,832,000	50,868,000	'
charges relating to business disposition	285,000	10,116,000	805,000	38,902,000	'
Disposition of business, after tax	'	9,000,000	'	27,000,000	'
Separation, Benefit Plan Termination and Related Costs	3,642,000	648,000	16,922,000	4,836,000	'
Acquisition Costs, Period Cost	0	0	0	2,300,000	'
Other charges	$3,999,000	$61,632,000	$25,559,000	$96,906,000	'

Significant_Accounting_Policie9

Significant Accounting Policies Restructuring and Other Related Charges (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Restructuring Cost and Reserve [Line Items]	'	'
Restructuring Reserve	$3	$5
Employee Severance [Member]	'	'
Restructuring Cost and Reserve [Line Items]	'	'
Restructuring Reserve, Cumulative Payments of Severance and other employee costs	$3	'

Recovered_Sheet1

Significant Accounting Policies Common Stock Repurchase Program (Details) (USD $)	9 Months Ended
Share data in Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Significant Accounting Policies [Abstract]	'	'
Stock Repurchase Program, Remaining Authorized Repurchase Amount	$340,000,000	'
cumulative value of shares repurchased through stock repurchase program	1,000,000,000	'
cumulative common stock repurchased through repurchase program	27	'
Stock Repurchased During Period, Value	$160,000,000	$91,000,000
Stock Repurchased During Period, Shares	2.7	2.5

Recovered_Sheet2

Significant Accounting Policies Capped Call (Details) (USD $)	9 Months Ended
In Millions, except Per Share data, unless otherwise specified	Sep. 30, 2014
Shares received upon settlement of capped call	0.6
Economic value of shares received upon settlement of capped call	$38
Maximum [Member]	'
option indexed to Company's own stock - strike price	$41.05
Option indexed to Issuer's own equity, cap price	$56.88
Minimum [Member]	'
option indexed to Company's own stock - strike price	$40.96
Option indexed to Issuer's own equity, cap price	$56.75

Discontinued_operations_Detail

Discontinued operations (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Discontinued Operations Revenue, Net	$25,163,000	$65,833,000	$133,769,000	$198,672,000
Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax	-2,462,000	4,921,000	-998,000	22,651,000
Discontinued Operations Income Tax Expense (Benefit)	784,000	1,879,000	1,583,000	8,652,000
Discontinued Operations Income (loss) from operations, after tax, before impairment	-3,246,000	3,042,000	-2,581,000	13,999,000
Discontinued Operations Impairment	0	0	39,804,000	0
Proceeds from Divestiture of Businesses	'	'	71,194,000	11,083,000
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest	-3,246,000	3,042,000	-42,385,000	13,999,000
Hospice Disposal Group [Member]	'	'	'	'
Discontinued Operations Revenue, Net	25,163,000	52,774,000	123,071,000	158,240,000
Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax	-2,566,000	5,155,000	548,000	23,149,000
Discontinued Operations Income Tax Expense (Benefit)	664,000	1,972,000	2,344,000	8,856,000
Discontinued Operations Income (loss) from operations, after tax, before impairment	-3,230,000	'	-1,796,000	14,293,000
Discontinued Operations Impairment	0	0	39,804,000	0
Proceeds from Divestiture of Businesses	'	'	65,000,000	'
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax	'	'	4,000,000	'
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest	-3,230,000	3,183,000	-41,600,000	14,293,000
Retail Disposal Group [Member]	'	'	'	'
Discontinued Operations Revenue, Net	0	13,059,000	10,698,000	40,432,000
Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax	104,000	-234,000	-1,546,000	-498,000
Discontinued Operations Income Tax Expense (Benefit)	120,000	-93,000	-761,000	-204,000
Discontinued Operations Income (loss) from operations, after tax, before impairment	-16,000	'	-785,000	-294,000
Discontinued Operations Impairment	0	0	0	0
Proceeds from Divestiture of Businesses	'	'	6,000,000	'
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest	($16,000)	($141,000)	($785,000)	($294,000)

Goodwill_and_Other_Intangible_2

Goodwill and Other Intangible Assets Goodwill Changes (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Goodwill [Line Items]	'	'	'	'	'
Goodwill	$4,060,683,000	'	$4,060,683,000	'	$4,057,456,000
Reduction of Goodwill as a Result of Disposition	'	'	-41,000	'	'
Goodwill, Other Changes	'	'	3,268,000	'	'
Intangible amortization expense	8,000,000	8,000,000	24,000,000	25,000,000	'
Long Term Care Group [Member]	'	'	'	'	'
Goodwill [Line Items]	'	'	'	'	'
Goodwill	3,570,246,000	'	3,570,246,000	'	3,567,019,000
Reduction of Goodwill as a Result of Disposition	'	'	-41,000	'	'
Goodwill, Other Changes	'	'	3,268,000	'	'
specialty care group [Member]	'	'	'	'	'
Goodwill [Line Items]	'	'	'	'	'
Goodwill	490,437,000	'	490,437,000	'	490,437,000
Reduction of Goodwill as a Result of Disposition	'	'	0	'	'
Goodwill, Other Changes	'	'	$0	'	'

Debt_Details

Debt (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Debt Instrument [Line Items]	'	'	'	'	'
Gains (Losses) on Extinguishment of Debt	'	'	($8,419,000)	($55,652,000)	'
Long-term Debt, Gross	2,426,257,000	'	2,426,257,000	'	2,500,434,000
Interest rate swap agreements	18,041,000	'	18,041,000	'	18,671,000
Debt Instrument, Unamortized Discount	-537,115,000	'	-537,115,000	'	-573,082,000
Debt, Current	-495,713,000	'	-495,713,000	'	-527,204,000
Long-term Debt, Excluding Current Maturities	1,411,470,000	'	1,411,470,000	'	1,418,819,000
Debt Instrument, Interest Rate, Stated Percentage	7.75%	'	7.75%	'	'
Letters of Credit Outstanding, Amount	14,000,000	'	14,000,000	'	'
Derivative, Basis Spread on Variable Rate	4.19%	'	4.19%	'	'
Amortization of Financing Costs	1,000,000	1,000,000	3,000,000	3,000,000	'
Current Revolving Credit Facility [Member]	'	'	'	'	'
Debt Instrument [Line Items]	'	'	'	'	'
Long-term Debt, Gross	0	'	0	'	0
Senior Term Loan [Member]	'	'	'	'	'
Debt Instrument [Line Items]	'	'	'	'	'
Long-term Debt, Gross	382,500,000	'	382,500,000	'	398,438,000
Debt Instrument, Interest Rate, Stated Percentage	1.91%	'	1.91%	'	'
7.75% Senior Subordinated Notes, Due 2020 [Member]	'	'	'	'	'
Debt Instrument [Line Items]	'	'	'	'	'
Long-term Debt, Gross	400,000,000	'	400,000,000	'	400,000,000
3.75% Convertible Senior Subordinated Notes, due 2025 [Member]	'	'	'	'	'
Debt Instrument [Line Items]	'	'	'	'	'
Debt Instrument, Repurchased Face Amount	52,000,000	'	52,000,000	'	'
Cash Paid for Debt Repurchased	'	'	134,000,000	'	'
Long-term Debt, Gross	79,979,000	'	79,979,000	'	132,408,000
Debt Instrument, Unamortized Discount	-26,178,000	'	-26,178,000	'	-45,098,000
treasury stock method average share price to include dilutive securities	'	'	$26.84	'	'
conversion threshold	34.89	'	34.89	'	'
4.00% Junior Subordinated Convertible Debentures, due 2033 [Member]	'	'	'	'	'
Debt Instrument [Line Items]	'	'	'	'	'
Long-term Debt, Gross	307,122,000	'	307,122,000	'	307,153,000
Debt Instrument, Unamortized Discount	-118,998,000	'	-118,998,000	'	-121,017,000
treasury stock method average share price to include dilutive securities	'	'	$40.82	'	'
4.0% Junior Subordinated debt due 2033 [Domain]	'	'	'	'	'
Debt Instrument [Line Items]	'	'	'	'	'
conversion threshold	53.07	'	53.07	'	'
3.25% Convertible Senior Debentures, Due 2035 [Member]	'	'	'	'	'
Debt Instrument [Line Items]	'	'	'	'	'
Long-term Debt, Gross	427,500,000	'	427,500,000	'	427,500,000
Debt Instrument, Unamortized Discount	-22,081,000	'	-22,081,000	'	-34,374,000
treasury stock method average share price to include dilutive securities	'	'	$77.88	'	'
3.75% Convertible Senior Subordinated Notes Due 2042 [Member]	'	'	'	'	'
Debt Instrument [Line Items]	'	'	'	'	'
Long-term Debt, Gross	390,000,000	'	390,000,000	'	390,000,000
Debt Instrument, Unamortized Discount	-163,611,000	'	-163,611,000	'	-164,986,000
treasury stock method average share price to include dilutive securities	'	'	$41.05	'	'
conversion threshold	53.37	'	53.37	'	'
3.5% Convertible senior subordinated debt [Domain]	'	'	'	'	'
Debt Instrument [Line Items]	'	'	'	'	'
Long-term Debt, Gross	424,250,000	'	424,250,000	'	424,250,000
treasury stock method average share price to include dilutive securities	'	'	$70	'	'
Capitalized Lease and Other Debt Obligations [Member]	'	'	'	'	'
Debt Instrument [Line Items]	'	'	'	'	'
Long-term Debt, Gross	$14,906,000	'	$14,906,000	'	$20,685,000

Debt_Schedule_of_Convertible_D

Debt Schedule of Convertible Debt (Details) (USD $)	3 Months Ended		9 Months Ended		3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Jun. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014
					3.75% Convertible Senior Subordinated Notes, due 2025 [Member]	3.75% Convertible Senior Subordinated Notes, due 2025 [Member]	3.75% Convertible Senior Subordinated Notes, due 2025 [Member]	4.00% Junior Subordinated Convertible Debentures, due 2033 [Member]	3.25% Convertible Senior Debentures, Due 2035 [Member]	3.75% Convertible Senior Subordinated Notes Due 2042 [Member]	3.5% Convertible senior subordinated debt [Domain]
Debt Instrument [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Aggregate Principal of Convertible Debt, if Converted	$777,000,000	'	$777,000,000	'	'	'	'	'	'	'	'
Extinguishment of Debt, Amount	'	'	'	'	'	5,000,000	'	'	'	'	'
Debt Related Costs	72,000	50,868,000	7,832,000	50,868,000	8,000,000	'	'	'	'	'	'
Debt Instrument, Convertible, Carrying Amount of Equity Component	'	'	'	'	'	'	$6,913,000	$118,348,000	$245,433,000	$167,941,000	$208,200,000
Remaining amortization period for the debt discount (in years)	'	'	'	'	'	'	'11 years 91 days	'18 years 274 days	'1 year 91 days	'27 years 183 days	'29 years 146 days
Debt Instrument, Interest Rate, Effective Percentage	'	'	'	'	'	'	8.25%	8.01%	7.63%	7.30%	7.70%

Debt_Fair_Value_of_Financial_I

Debt Fair Value of Financial Instruments (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Long-term Debt, Gross	$2,426,257	$2,500,434
Debt Instrument, Unamortized Discount	537,115	573,082
7.75% Senior Subordinated Notes, Due 2020 [Member]	'	'
Long-term Debt, Gross	400,000	400,000
Long-term Debt, Fair Value	421,000	435,800
3.75% Convertible Senior Subordinated Notes, due 2025 [Member]	'	'
Long-term Debt, Gross	79,979	132,408
Long-term Debt, Fair Value	180,800	306,500
Long-term Debt	53,801	87,310
Debt Instrument, Unamortized Discount	26,178	45,098
4.00% Junior Subordinated Convertible Debentures, due 2033 [Member]	'	'
Long-term Debt, Gross	307,122	307,153
Long-term Debt, Fair Value	468,300	455,900
Long-term Debt	188,124	186,136
Debt Instrument, Unamortized Discount	118,998	121,017
3.25% Convertible Senior Debentures, Due 2035 [Member]	'	'
Long-term Debt, Gross	427,500	427,500
Long-term Debt, Fair Value	450,000	457,400
Long-term Debt	405,419	393,126
Debt Instrument, Unamortized Discount	22,081	34,374
3.75% Convertible Senior Subordinated Notes Due 2042 [Member]	'	'
Long-term Debt, Gross	390,000	390,000
Long-term Debt, Fair Value	608,000	592,800
Long-term Debt	226,389	225,014
Debt Instrument, Unamortized Discount	163,611	164,986
3.50% Convertible Senior Subordianted Notes, Due 2044 [Member]	'	'
Long-term Debt, Gross	424,250	424,250
Long-term Debt, Fair Value	469,600	428,500
Long-term Debt	218,003	216,643
Debt Instrument, Unamortized Discount	$206,247	$207,607

Debt_Contingent_interest_Detai

Debt Contingent interest (Details) (USD $)	9 Months Ended
	Sep. 30, 2014
	Rate
December 12, 2013 [Member]	'
Contingent Interest, Accrual Period, Start Date	15-Dec-13
Contingent Interest, Accrual Period, End Date	14-Mar-14
Debt instrument, convertible, contingent interest rate	0.13%
Contingent Interest, Trading Price Period End Date	12-Dec-13
contingent cash interest paid per stated liquidation amount	$0.09
Contingent Interest, Payment Date	17-Mar-14
March 13, 2014 [Member]	'
Contingent Interest, Accrual Period, Start Date	15-Mar-14
Contingent Interest, Accrual Period, End Date	14-Jun-14
Debt instrument, convertible, contingent interest rate	0.13%
Contingent Interest, Trading Price Period End Date	13-Mar-14
contingent cash interest paid per stated liquidation amount	0.09
Contingent Interest, Payment Date	16-Jun-14
June 12, 2014 [Member]	'
Contingent Interest, Accrual Period, Start Date	15-Jun-14
Contingent Interest, Accrual Period, End Date	15-Sep-14
Debt instrument, convertible, contingent interest rate	0.13%
Contingent Interest, Trading Price Period End Date	12-Jun-14
contingent cash interest paid per stated liquidation amount	0.09
Contingent Interest, Payment Date	15-Sep-14
September 12, 2014 [Member]	'
Contingent Interest, Accrual Period, Start Date	15-Sep-14
Contingent Interest, Accrual Period, End Date	14-Dec-14
Debt instrument, convertible, contingent interest rate	0.13%
Contingent Interest, Trading Price Period End Date	12-Sep-14
contingent cash interest paid per stated liquidation amount	$0.10
Contingent Interest, Payment Date	15-Dec-14

Earnings_Loss_Per_Share_Data_D

Earnings (Loss) Per Share Data (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Earnings Per Share [Abstract]	'	'	'	'
Income (Loss) from Continuing Operations Attributable to Parent	$68,077	($69,351)	$192,961	$26,265
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	64,831	-66,309	150,576	40,264
Earnings (loss) per common share - Basic:	'	'	'	'
Net income	$0.67	($0.65)	$1.54	$0.39
Effect of Dilutive Securities [Abstract]	'	'	'	'
Convertible Securities	66	0	198	212
Stock options, warrants and awards	0	0	0	0
Convertible Securities (in shares)	7,945,000	0	8,283,000	6,360,000
Stock options, warrants and awards, common shares (in shares)	584,000	0	646,000	628,000
Income from continuing operations plus assumed conversions	68,143	-69,351	193,159	26,477
Earnings (loss) per common share - Diluted:	'	'	'	'
Net income plus assumed conversions	64,897	-66,309	150,774	40,476
Diluted shares	105,548,000	101,811,000	106,450,000	109,612,000
Diluted earnings per share	$0.61	($0.65)	$1.42	$0.37
Aggregate number of stock options, warrants and awards excluded from the computation of diluted EPS (in shares)	'	'	'	1,000,000
Income (Loss) from Continuing Operations, Per Basic Share	$0.70	($0.68)	$1.98	$0.26
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest	($3,246)	$3,042	($42,385)	$13,999
Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share	($0.03)	$0.03	($0.40)	$0.13
Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share	($0.03)	$0.03	($0.43)	$0.14
Income (Loss) from Continuing Operations, Per Diluted Share	$0.65	($0.68)	$1.81	$0.24
Weighted Average Number of Shares Outstanding, Basic	97,019,000	101,811,000	97,521,000	102,624,000

EarningsPer_Share_Data_Convert

EarningsPer Share Data Convertible Debt (Details) (USD $)	9 Months Ended
	Sep. 30, 2014
3.75% Convertible Senior Subordinated Notes, due 2025 [Member]	'
treasury stock method average share price to include dilutive securities	$26.84
4.00% Junior Subordinated Convertible Debentures, due 2033 [Member]	'
treasury stock method average share price to include dilutive securities	$40.82
3.25% Convertible Senior Debentures, Due 2035 [Member]	'
treasury stock method average share price to include dilutive securities	$77.88
3.75% Convertible Senior Subordinated Notes Due 2042 [Member]	'
treasury stock method average share price to include dilutive securities	$41.05
3.5% Convertible senior subordinated debt [Domain]	'
treasury stock method average share price to include dilutive securities	$70

Commitments_and_Contingencies_

Commitments and Contingencies (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Commitments and Contingencies Disclosure [Abstract]	'	'	'	'
Settlement, litigation and other related charges	$12,868	$143,484	$27,467	$169,615

Segment_Information_Segment_De1

Segment Information Segment Details (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Revenue, Net	$1,608,055	$1,515,168	$4,789,677	$4,477,229
Depreciation and amortization expense	-33,332	-34,040	-100,429	-99,527
Settlement, litigation and other related charges	-12,868	-143,484	-27,467	-169,615
Other charges	-3,999	-61,632	-25,559	96,906
Operating Income (Loss)	135,742	-60,776	398,740	154,280
Corporate/Other [Member]	'	'	'	'
Revenue, Net	77	160	266	1,330
Depreciation and amortization expense	-14,849	-14,953	-44,798	-42,318
Settlement, litigation and other related charges	0	0	0	0
Other charges	-446	-50,868	-16,575	-52,841
Operating Income (Loss)	-40,746	-91,828	-142,719	-187,678
Long Term Care Group [Member]	'	'	'	'
Revenue, Net	1,183,398	1,157,951	3,565,092	3,458,772
Depreciation and amortization expense	-17,405	-17,919	-52,258	-53,801
Settlement, litigation and other related charges	-12,868	-143,484	-27,467	-169,615
Other charges	-3,553	-10,764	-8,984	-44,065
Operating Income (Loss)	142,285	4,207	444,402	259,953
specialty care group [Member]	'	'	'	'
Revenue, Net	424,580	357,057	1,224,319	1,017,127
Depreciation and amortization expense	-1,078	-1,168	-3,373	-3,408
Settlement, litigation and other related charges	0	0	0	0
Other charges	0	0	0	0
Operating Income (Loss)	$34,203	$26,845	$97,057	$82,005

Guarantor_Subsidiaries_Details

Guarantor Subsidiaries (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Summary Consolidating Statements of Income [Abstract]	'	'	'	'	'
Net sales	$1,608,055	$1,515,168	$4,789,677	$4,477,229	'
Cost of sales	1,256,595	1,163,197	3,725,533	3,416,039	'
Gross profit	351,460	351,971	1,064,144	1,061,190	'
Selling, general and administrative expenses	178,940	182,668	549,816	565,276	'
Provision for doubtful accounts	19,911	24,963	62,562	75,113	'
Settlement, litigation and other related charges	12,868	143,484	27,467	169,615	'
Other miscellaneous charges	3,999	61,632	25,559	96,906	'
Operating income	135,742	-60,776	398,740	154,280	'
Interest expense, net of investment income	-28,717	-34,925	-88,138	-94,011	'
Income before income taxes	107,025	-95,701	310,602	60,269	'
Income tax (benefit) expense	38,948	-26,350	117,641	34,004	'
Income (Loss) from Continuing Operations Attributable to Parent	68,077	-69,351	192,961	26,265	'
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest	-3,246	3,042	-42,385	13,999	'
Equity of net income (loss) of subsidiaries	0	0	0	0	'
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	64,831	-66,309	150,576	40,264	'
Comprehensive income (loss)	65,170	-66,305	151,182	40,170	'
ASSETS	'	'	'	'	'
Cash and Cash Equivalents, at Carrying Value	286,943	498,263	286,943	498,263	'
Accounts Receivable, Net, Current	651,224	'	651,224	'	695,684
Inventory, Net	494,563	'	494,563	'	512,418
Deferred Tax Assets, Net of Valuation Allowance, Current	56,084	'	56,084	'	135,094
Other Assets, Current	315,165	'	315,165	'	265,536
Assets of Disposal Group, Including Discontinued Operation, Current	0	'	0	'	49,995
Total current assets	1,803,979	'	1,803,979	'	2,014,728
Property, Plant and Equipment, Net	330,601	'	330,601	'	305,888
Goodwill	4,060,683	'	4,060,683	'	4,057,456
Intangible Assets, Net (Excluding Goodwill)	106,425	'	106,425	'	129,974
Other Assets, Noncurrent	95,649	'	95,649	'	96,722
Disposal Group, Including Discontinued Operation, Long Lived Assets, Noncurrent	0	'	0	'	87,078
Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures	0	'	0	'	0
Total assets	6,397,337	'	6,397,337	'	6,691,846
LIABILITIES AND STOCKHOLDERS' EQUITY	'	'	'	'	'
Current liabilities of continuing operations, excluding current portion of long-term debt	443,006	'	443,006	'	587,107
Debt, Current	495,713	'	495,713	'	527,204
Liabilities of Disposal Group, Including Discontinued Operation, Current	0	'	0	'	18,846
Liabilities of Disposal Group, Including Discontinued Operation, Noncurrent	0	'	0	'	1,398
Temporary Equity, Liquidation Preference	308,787	'	308,787	'	331,101
Long-term Debt, Excluding Current Maturities	1,411,470	'	1,411,470	'	1,418,819
Deferred income tax liabilities	1,022,857	'	1,022,857	'	1,012,733
Other noncurrent liabilities	60,701	'	60,701	'	53,835
Stockholders' equity	2,654,803	'	2,654,803	'	2,740,803
Total liabilities and stockholders' equity	6,397,337	'	6,397,337	'	6,691,846
Cash flows from operating activities:	'	'	'	'	'
Net cash flows (used in) from operating activities	'	'	355,417	454,665	'
Cash flows from investing activities:	'	'	'	'	'
Acquisition of businesses, net of cash received	'	'	0	3,798	'
Proceeds from Divestiture of Businesses	'	'	71,194	11,083	'
Capital expenditures	'	'	-67,871	-73,279	'
Other Investing Activities	'	'	881	407	'
Net cash flows used in investing activities	'	'	2,442	-66,401	'
Cash flows from financing activities:	'	'	'	'	'
Payments on Term Loans	'	'	-15,938	-15,938	'
Payments on long-term borrowings and obligations	'	'	-176,983	-190,403	'
Payments of Debt Issuance Costs	'	'	0	-4,851	'
Proceeds from (Repayments of) Bank Overdrafts	'	'	-19,786	-11,490	'
Payments for Omnicare common stock repurchase	'	'	-160,438	-91,259	'
Dividends paid	'	'	-58,419	-43,011	'
Proceeds from (payments for) Other Financing Activities including disc Ops	'	'	4,647	20,162	'
Net Cash Provided by (Used in) Financing Activities	'	'	-426,917	-336,790	'
Net increase (decrease) in cash and cash equivalents	'	'	-69,058	51,474	'
Cash and cash equivalents at beginning of period	'	'	356,001	444,620	'
Cash and cash equivalents at end of period	286,943	498,263	286,943	498,263	'
Net Cash Provided by (Used in) Discontinued Operations	'	'	0	-2,169	'
Net Cash Provided by (Used in) Continuing Operations	'	'	-69,058	53,643	'
Parent Company [Member]	'	'	'	'	'
Summary Consolidating Statements of Income [Abstract]	'	'	'	'	'
Net sales	0	0	0	0	'
Cost of sales	0	0	0	0	'
Gross profit	0	0	0	0	'
Selling, general and administrative expenses	1,053	1,504	3,481	3,696	'
Provision for doubtful accounts	0	0	0	0	'
Settlement, litigation and other related charges	0	0	0	0	'
Other miscellaneous charges	0	0	0	0	'
Operating income	-1,053	-1,504	-3,481	-3,696	'
Interest expense, net of investment income	-28,456	-34,583	-86,676	-92,757	'
Income before income taxes	-29,509	-36,087	-90,157	-96,453	'
Income tax (benefit) expense	-11,503	-14,190	-34,846	-37,395	'
Income (Loss) from Continuing Operations Attributable to Parent	-18,006	-21,897	-55,311	-59,058	'
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest	0	0	0	0	'
Equity of net income (loss) of subsidiaries	82,837	-44,412	205,887	99,322	'
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	64,831	-66,309	150,576	40,264	'
Comprehensive income (loss)	65,170	-66,305	151,182	40,170	'
ASSETS	'	'	'	'	'
Cash and Cash Equivalents, at Carrying Value	248,786	428,003	248,786	428,003	'
Accounts Receivable, Net, Current	0	'	0	'	0
Inventory, Net	0	'	0	'	0
Deferred Tax Assets, Net of Valuation Allowance, Current	0	'	0	'	0
Other Assets, Current	30,506	'	30,506	'	1,989
Assets of Disposal Group, Including Discontinued Operation, Current	0	'	0	'	0
Total current assets	279,292	'	279,292	'	277,899
Property, Plant and Equipment, Net	0	'	0	'	0
Goodwill	0	'	0	'	0
Intangible Assets, Net (Excluding Goodwill)	0	'	0	'	0
Other Assets, Noncurrent	38,039	'	38,039	'	41,825
Disposal Group, Including Discontinued Operation, Long Lived Assets, Noncurrent	0	'	0	'	0
Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures	4,952,869	'	4,952,869	'	5,131,280
Total assets	5,270,200	'	5,270,200	'	5,451,004
LIABILITIES AND STOCKHOLDERS' EQUITY	'	'	'	'	'
Current liabilities of continuing operations, excluding current portion of long-term debt	30,230	'	30,230	'	83,028
Debt, Current	495,713	'	495,713	'	527,204
Liabilities of Disposal Group, Including Discontinued Operation, Current	0	'	0	'	0
Temporary Equity, Liquidation Preference	308,787	'	308,787	'	331,101
Long-term Debt, Excluding Current Maturities	1,402,712	'	1,402,712	'	1,405,628
Deferred income tax liabilities	377,955	'	377,955	'	363,240
Other noncurrent liabilities	0	'	0	'	0
Stockholders' equity	2,654,803	'	2,654,803	'	2,740,803
Total liabilities and stockholders' equity	5,270,200	'	5,270,200	'	5,451,004
Cash flows from operating activities:	'	'	'	'	'
Net cash flows (used in) from operating activities	'	'	-68,865	-42,519	'
Cash flows from investing activities:	'	'	'	'	'
Acquisition of businesses, net of cash received	'	'	'	0	'
Proceeds from Divestiture of Businesses	'	'	0	0	'
Capital expenditures	'	'	0	0	'
Other Investing Activities	'	'	0	227	'
Net cash flows used in investing activities	'	'	0	-227	'
Cash flows from financing activities:	'	'	'	'	'
Payments on Term Loans	'	'	-15,938	-15,938	'
Payments on long-term borrowings and obligations	'	'	-176,983	-190,403	'
Payments of Debt Issuance Costs	'	'	'	-4,851	'
Proceeds from (Repayments of) Bank Overdrafts	'	'	-10,036	-10,232	'
Payments for Omnicare common stock repurchase	'	'	-160,438	-91,259	'
Dividends paid	'	'	-58,419	-43,011	'
Proceeds from (payments for) Other Financing Activities including disc Ops	'	'	463,555	442,769	'
Net Cash Provided by (Used in) Financing Activities	'	'	41,741	87,075	'
Net increase (decrease) in cash and cash equivalents	'	'	-27,124	44,329	'
Cash and cash equivalents at beginning of period	'	'	275,910	383,674	'
Cash and cash equivalents at end of period	248,786	428,003	248,786	428,003	'
Net Cash Provided by (Used in) Discontinued Operations	'	'	0	0	'
Cash and Cash Equivalents Period Increase (Decrease) from Continuing Operations	'	'	-27,124	44,329	'
Guarantor Subsidiaries [Member] | Convertible Senior Debentures [Member]	'	'	'	'	'
Summary Consolidating Statements of Income [Abstract]	'	'	'	'	'
Net sales	0	0	0	0	'
Cost of sales	0	0	0	0	'
Gross profit	0	0	0	0	'
Selling, general and administrative expenses	430	417	1,309	1,233	'
Provision for doubtful accounts	0	0	0	0	'
Settlement, litigation and other related charges	0	0	0	0	'
Other miscellaneous charges	0	0	0	0	'
Operating income	-430	-417	-1,309	-1,233	'
Interest expense, net of investment income	0	0	0	0	'
Income before income taxes	-430	-417	-1,309	-1,233	'
Income tax (benefit) expense	-168	-164	-506	-478	'
Income (Loss) from Continuing Operations Attributable to Parent	-262	-253	-803	-755	'
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest	0	0	0	0	'
Equity of net income (loss) of subsidiaries	0	0	0	0	'
Income (Loss) from Continuing Operations, Including Portion Attributable to Noncontrolling Interest	-262	-253	-803	-755	'
Comprehensive income (loss)	-262	-253	-803	-755	'
ASSETS	'	'	'	'	'
Cash and Cash Equivalents, at Carrying Value	0	0	0	0	'
Accounts Receivable, Net, Current	192	'	192	'	210
Inventory, Net	0	'	0	'	0
Deferred Tax Assets, Net of Valuation Allowance, Current	0	'	0	'	0
Other Assets, Current	0	'	0	'	0
Assets of Disposal Group, Including Discontinued Operation, Current	0	'	0	'	0
Total current assets	192	'	192	'	210
Property, Plant and Equipment, Net	13	'	13	'	19
Goodwill	0	'	0	'	0
Intangible Assets, Net (Excluding Goodwill)	0	'	0	'	0
Other Assets, Noncurrent	19	'	19	'	19
Disposal Group, Including Discontinued Operation, Long Lived Assets, Noncurrent	0	'	0	'	0
Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures	0	'	0	'	0
Total assets	224	'	224	'	248
LIABILITIES AND STOCKHOLDERS' EQUITY	'	'	'	'	'
Current liabilities of continuing operations, excluding current portion of long-term debt	0	'	0	'	0
Debt, Current	0	'	0	'	0
Liabilities of Disposal Group, Including Discontinued Operation, Current	0	'	0	'	0
Temporary Equity, Liquidation Preference	0	'	0	'	0
Long-term Debt, Excluding Current Maturities	0	'	0	'	0
Deferred income tax liabilities	0	'	0	'	0
Other noncurrent liabilities	0	'	0	'	0
Stockholders' equity	224	'	224	'	248
Total liabilities and stockholders' equity	224	'	224	'	248
Cash flows from operating activities:	'	'	'	'	'
Net cash flows (used in) from operating activities	'	'	0	0	'
Cash flows from investing activities:	'	'	'	'	'
Acquisition of businesses, net of cash received	'	'	'	0	'
Proceeds from Divestiture of Businesses	'	'	0	0	'
Capital expenditures	'	'	0	0	'
Other Investing Activities	'	'	0	0	'
Net cash flows used in investing activities	'	'	0	0	'
Cash flows from financing activities:	'	'	'	'	'
Payments on Term Loans	'	'	0	0	'
Payments on long-term borrowings and obligations	'	'	0	0	'
Payments of Debt Issuance Costs	'	'	'	0	'
Proceeds from (Repayments of) Bank Overdrafts	'	'	0	0	'
Payments for Omnicare common stock repurchase	'	'	0	0	'
Dividends paid	'	'	0	0	'
Proceeds from (payments for) Other Financing Activities including disc Ops	'	'	0	0	'
Net Cash Provided by (Used in) Financing Activities	'	'	0	0	'
Net increase (decrease) in cash and cash equivalents	'	'	0	0	'
Cash and cash equivalents at beginning of period	'	'	0	0	'
Cash and cash equivalents at end of period	0	0	0	0	'
Net Cash Provided by (Used in) Discontinued Operations	'	'	0	0	'
Cash and Cash Equivalents Period Increase (Decrease) from Continuing Operations	'	'	0	0	'
Guarantor Subsidiaries [Member] | Guaranteed Senior Notes Payable [Member]	'	'	'	'	'
Summary Consolidating Statements of Income [Abstract]	'	'	'	'	'
Net sales	1,576,811	1,485,545	4,697,025	4,383,420	'
Cost of sales	1,236,644	1,146,140	3,669,163	3,362,356	'
Gross profit	340,167	339,405	1,027,862	1,021,064	'
Selling, general and administrative expenses	172,857	176,970	531,899	547,264	'
Provision for doubtful accounts	19,570	24,487	61,202	73,671	'
Settlement, litigation and other related charges	12,868	143,484	27,467	169,615	'
Other miscellaneous charges	3,999	54,361	25,559	89,635	'
Operating income	130,873	-59,897	381,735	140,879	'
Interest expense, net of investment income	-261	-344	-1,462	-890	'
Income before income taxes	130,612	-60,241	380,273	139,989	'
Income tax (benefit) expense	48,139	-15,270	144,569	62,093	'
Income (Loss) from Continuing Operations Attributable to Parent	82,473	-44,971	235,704	77,896	'
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest	-526	-2,100	-1,245	-9,115	'
Equity of net income (loss) of subsidiaries	0	0	0	0	'
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	81,947	-47,071	234,459	68,781	'
Comprehensive income (loss)	81,947	-47,071	234,459	68,781	'
ASSETS	'	'	'	'	'
Cash and Cash Equivalents, at Carrying Value	26,183	57,940	26,183	57,940	'
Accounts Receivable, Net, Current	648,877	'	648,877	'	693,729
Inventory, Net	486,761	'	486,761	'	505,567
Deferred Tax Assets, Net of Valuation Allowance, Current	56,135	'	56,135	'	135,148
Other Assets, Current	257,138	'	257,138	'	242,166
Assets of Disposal Group, Including Discontinued Operation, Current	0	'	0	'	12,305
Total current assets	1,475,094	'	1,475,094	'	1,656,965
Property, Plant and Equipment, Net	325,405	'	325,405	'	301,200
Goodwill	4,031,878	'	4,031,878	'	4,028,651
Intangible Assets, Net (Excluding Goodwill)	104,884	'	104,884	'	127,798
Other Assets, Noncurrent	57,571	'	57,571	'	54,834
Disposal Group, Including Discontinued Operation, Long Lived Assets, Noncurrent	0	'	0	'	3,762
Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures	0	'	0	'	0
Total assets	5,994,832	'	5,994,832	'	6,173,210
LIABILITIES AND STOCKHOLDERS' EQUITY	'	'	'	'	'
Current liabilities of continuing operations, excluding current portion of long-term debt	472,964	'	472,964	'	793,461
Debt, Current	0	'	0	'	0
Liabilities of Disposal Group, Including Discontinued Operation, Current	0	'	0	'	1,894
Liabilities of Disposal Group, Including Discontinued Operation, Noncurrent	0	'	0	'	176
Temporary Equity, Liquidation Preference	0	'	0	'	0
Long-term Debt, Excluding Current Maturities	8,758	'	8,758	'	13,191
Deferred income tax liabilities	645,327	'	645,327	'	635,640
Other noncurrent liabilities	58,891	'	58,891	'	52,072
Stockholders' equity	4,808,892	'	4,808,892	'	4,676,776
Total liabilities and stockholders' equity	5,994,832	'	5,994,832	'	6,173,210
Cash flows from operating activities:	'	'	'	'	'
Net cash flows (used in) from operating activities	'	'	425,119	507,984	'
Cash flows from investing activities:	'	'	'	'	'
Acquisition of businesses, net of cash received	'	'	'	3,798	'
Proceeds from Divestiture of Businesses	'	'	71,194	675	'
Capital expenditures	'	'	-67,217	-71,984	'
Other Investing Activities	'	'	881	180	'
Net cash flows used in investing activities	'	'	3,096	-75,287	'
Cash flows from financing activities:	'	'	'	'	'
Payments on Term Loans	'	'	0	0	'
Payments on long-term borrowings and obligations	'	'	0	'	'
Payments of Debt Issuance Costs	'	'	'	0	'
Proceeds from (Repayments of) Bank Overdrafts	'	'	-9,750	-1,258	'
Payments for Omnicare common stock repurchase	'	'	0	0	'
Dividends paid	'	'	0	0	'
Proceeds from (payments for) Other Financing Activities including disc Ops	'	'	-458,908	-422,607	'
Net Cash Provided by (Used in) Financing Activities	'	'	-468,658	-423,865	'
Net increase (decrease) in cash and cash equivalents	'	'	-40,443	8,832	'
Cash and cash equivalents at beginning of period	'	'	68,050	49,108	'
Cash and cash equivalents at end of period	26,183	57,940	26,183	57,940	'
Net Cash Provided by (Used in) Discontinued Operations	'	'	1,424	0	'
Cash and Cash Equivalents Period Increase (Decrease) from Continuing Operations	'	'	-41,867	8,832	'
Non-Guarantor Subsidiaries [Member] | Convertible Senior Debentures [Member]	'	'	'	'	'
Summary Consolidating Statements of Income [Abstract]	'	'	'	'	'
Net sales	1,608,055	1,515,168	4,789,677	4,477,229	'
Cost of sales	1,256,595	1,163,197	3,725,533	3,416,039	'
Gross profit	351,460	351,971	1,064,144	1,061,190	'
Selling, general and administrative expenses	177,457	180,747	545,026	560,347	'
Provision for doubtful accounts	19,911	24,963	62,562	75,113	'
Settlement, litigation and other related charges	12,868	143,484	27,467	169,615	'
Other miscellaneous charges	3,999	61,632	25,559	96,906	'
Operating income	137,225	-58,855	403,530	159,209	'
Interest expense, net of investment income	-261	-342	-1,462	-1,254	'
Income before income taxes	136,964	-59,197	402,068	157,955	'
Income tax (benefit) expense	50,619	-11,996	152,993	71,877	'
Income (Loss) from Continuing Operations Attributable to Parent	86,345	-47,201	249,075	86,078	'
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest	-3,246	3,042	-42,385	13,999	'
Equity of net income (loss) of subsidiaries	0	0	0	0	'
Income (Loss) from Continuing Operations, Including Portion Attributable to Noncontrolling Interest	83,099	-44,159	206,690	100,077	'
Comprehensive income (loss)	83,099	-44,159	206,690	100,077	'
ASSETS	'	'	'	'	'
Cash and Cash Equivalents, at Carrying Value	38,157	70,260	38,157	70,260	'
Accounts Receivable, Net, Current	651,224	'	651,224	'	695,684
Inventory, Net	494,563	'	494,563	'	512,418
Deferred Tax Assets, Net of Valuation Allowance, Current	56,084	'	56,084	'	135,094
Other Assets, Current	284,659	'	284,659	'	263,547
Assets of Disposal Group, Including Discontinued Operation, Current	0	'	0	'	49,995
Total current assets	1,524,687	'	1,524,687	'	1,736,829
Property, Plant and Equipment, Net	330,588	'	330,588	'	305,869
Goodwill	4,060,683	'	4,060,683	'	4,057,456
Intangible Assets, Net (Excluding Goodwill)	106,425	'	106,425	'	129,974
Other Assets, Noncurrent	57,591	'	57,591	'	54,878
Disposal Group, Including Discontinued Operation, Long Lived Assets, Noncurrent	0	'	0	'	87,078
Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures	0	'	0	'	0
Total assets	6,079,974	'	6,079,974	'	6,372,084
LIABILITIES AND STOCKHOLDERS' EQUITY	'	'	'	'	'
Current liabilities of continuing operations, excluding current portion of long-term debt	412,968	'	412,968	'	504,289
Debt, Current	0	'	0	'	0
Liabilities of Disposal Group, Including Discontinued Operation, Current	0	'	0	'	18,846
Liabilities of Disposal Group, Including Discontinued Operation, Noncurrent	0	'	0	'	1,398
Temporary Equity, Liquidation Preference	0	'	0	'	0
Long-term Debt, Excluding Current Maturities	8,758	'	8,758	'	13,191
Deferred income tax liabilities	644,902	'	644,902	'	649,493
Other noncurrent liabilities	60,701	'	60,701	'	53,835
Stockholders' equity	4,952,645	'	4,952,645	'	5,131,032
Total liabilities and stockholders' equity	6,079,974	'	6,079,974	'	6,372,084
Cash flows from operating activities:	'	'	'	'	'
Net cash flows (used in) from operating activities	'	'	424,282	497,184	'
Cash flows from investing activities:	'	'	'	'	'
Acquisition of businesses, net of cash received	'	'	'	3,798	'
Proceeds from Divestiture of Businesses	'	'	71,194	11,083	'
Capital expenditures	'	'	-67,871	-73,279	'
Other Investing Activities	'	'	881	180	'
Net cash flows used in investing activities	'	'	2,442	-66,174	'
Cash flows from financing activities:	'	'	'	'	'
Payments on Term Loans	'	'	0	0	'
Payments on long-term borrowings and obligations	'	'	0	0	'
Payments of Debt Issuance Costs	'	'	'	0	'
Proceeds from (Repayments of) Bank Overdrafts	'	'	-9,750	-1,258	'
Payments for Omnicare common stock repurchase	'	'	0	0	'
Dividends paid	'	'	0	0	'
Proceeds from (payments for) Other Financing Activities including disc Ops	'	'	-458,908	-422,607	'
Net Cash Provided by (Used in) Financing Activities	'	'	-468,658	-423,865	'
Net increase (decrease) in cash and cash equivalents	'	'	-41,934	7,145	'
Cash and cash equivalents at beginning of period	'	'	80,091	60,946	'
Cash and cash equivalents at end of period	38,157	70,260	38,157	70,260	'
Net Cash Provided by (Used in) Discontinued Operations	'	'	0	-2,169	'
Cash and Cash Equivalents Period Increase (Decrease) from Continuing Operations	'	'	-41,934	9,314	'
Non-Guarantor Subsidiaries [Member] | Guaranteed Senior Notes Payable [Member]	'	'	'	'	'
Summary Consolidating Statements of Income [Abstract]	'	'	'	'	'
Net sales	31,244	29,623	92,652	93,809	'
Cost of sales	19,951	17,057	56,370	53,683	'
Gross profit	11,293	12,566	36,282	40,126	'
Selling, general and administrative expenses	5,030	4,194	14,436	14,316	'
Provision for doubtful accounts	341	476	1,360	1,442	'
Settlement, litigation and other related charges	0	0	0	0	'
Other miscellaneous charges	0	7,271	0	7,271	'
Operating income	5,922	625	20,486	17,097	'
Interest expense, net of investment income	0	2	0	-364	'
Income before income taxes	5,922	627	20,486	16,733	'
Income tax (benefit) expense	2,312	3,110	7,918	9,306	'
Income (Loss) from Continuing Operations Attributable to Parent	3,610	-2,483	12,568	7,427	'
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest	-2,720	5,142	-41,140	23,114	'
Equity of net income (loss) of subsidiaries	0	0	0	0	'
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	890	2,659	-28,572	30,541	'
Comprehensive income (loss)	890	2,659	-28,572	30,541	'
ASSETS	'	'	'	'	'
Cash and Cash Equivalents, at Carrying Value	11,974	12,320	11,974	12,320	'
Accounts Receivable, Net, Current	94,673	'	94,673	'	315,323
Inventory, Net	7,802	'	7,802	'	6,851
Deferred Tax Assets, Net of Valuation Allowance, Current	374	'	374	'	0
Other Assets, Current	27,521	'	27,521	'	21,381
Assets of Disposal Group, Including Discontinued Operation, Current	0	'	0	'	37,690
Total current assets	142,344	'	142,344	'	393,286
Property, Plant and Equipment, Net	5,196	'	5,196	'	4,688
Goodwill	28,805	'	28,805	'	28,805
Intangible Assets, Net (Excluding Goodwill)	1,541	'	1,541	'	2,176
Other Assets, Noncurrent	39	'	39	'	63
Disposal Group, Including Discontinued Operation, Long Lived Assets, Noncurrent	0	'	0	'	83,316
Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures	0	'	0	'	0
Total assets	177,925	'	177,925	'	512,334
LIABILITIES AND STOCKHOLDERS' EQUITY	'	'	'	'	'
Current liabilities of continuing operations, excluding current portion of long-term debt	32,138	'	32,138	'	23,986
Debt, Current	0	'	0	'	0
Liabilities of Disposal Group, Including Discontinued Operation, Current	0	'	0	'	16,952
Liabilities of Disposal Group, Including Discontinued Operation, Noncurrent	0	'	0	'	1,222
Temporary Equity, Liquidation Preference	0	'	0	'	0
Long-term Debt, Excluding Current Maturities	0	'	0	'	0
Deferred income tax liabilities	0	'	0	'	13,907
Other noncurrent liabilities	1,810	'	1,810	'	1,763
Stockholders' equity	143,977	'	143,977	'	454,504
Total liabilities and stockholders' equity	177,925	'	177,925	'	512,334
Cash flows from operating activities:	'	'	'	'	'
Net cash flows (used in) from operating activities	'	'	-837	-10,800	'
Cash flows from investing activities:	'	'	'	'	'
Acquisition of businesses, net of cash received	'	'	'	0	'
Proceeds from Divestiture of Businesses	'	'	0	10,408	'
Capital expenditures	'	'	-654	-1,295	'
Other Investing Activities	'	'	0	0	'
Net cash flows used in investing activities	'	'	-654	9,113	'
Cash flows from financing activities:	'	'	'	'	'
Payments on Term Loans	'	'	0	0	'
Payments on long-term borrowings and obligations	'	'	0	'	'
Payments of Debt Issuance Costs	'	'	'	0	'
Proceeds from (Repayments of) Bank Overdrafts	'	'	0	0	'
Payments for Omnicare common stock repurchase	'	'	0	0	'
Dividends paid	'	'	0	0	'
Proceeds from (payments for) Other Financing Activities including disc Ops	'	'	0	0	'
Net Cash Provided by (Used in) Financing Activities	'	'	0	0	'
Net increase (decrease) in cash and cash equivalents	'	'	-1,491	-1,687	'
Cash and cash equivalents at beginning of period	'	'	12,041	11,838	'
Cash and cash equivalents at end of period	11,974	12,320	11,974	12,320	'
Net Cash Provided by (Used in) Discontinued Operations	'	'	-1,424	-2,169	'
Cash and Cash Equivalents Period Increase (Decrease) from Continuing Operations	'	'	-67	482	'
Consolidating, Eliminating Adjustments [Member]	'	'	'	'	'
Summary Consolidating Statements of Income [Abstract]	'	'	'	'	'
Comprehensive income (loss)	-82,837	44,412	-205,887	-99,322	'
Consolidating, Eliminating Adjustments [Member] | Convertible Senior Debentures [Member]	'	'	'	'	'
Summary Consolidating Statements of Income [Abstract]	'	'	'	'	'
Net sales	0	0	0	0	'
Cost of sales	0	0	0	0	'
Gross profit	0	0	0	0	'
Selling, general and administrative expenses	0	0	0	0	'
Provision for doubtful accounts	0	0	0	0	'
Settlement, litigation and other related charges	0	0	0	0	'
Other miscellaneous charges	0	0	0	0	'
Operating income	0	0	0	0	'
Interest expense, net of investment income	0	0	0	0	'
Income before income taxes	0	0	0	0	'
Income tax (benefit) expense	0	0	0	0	'
Income (Loss) from Continuing Operations Attributable to Parent	0	0	0	0	'
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest	0	0	0	0	'
Equity of net income (loss) of subsidiaries	-82,837	44,412	-205,887	-99,322	'
Income (Loss) from Continuing Operations, Including Portion Attributable to Noncontrolling Interest	-82,837	44,412	-205,887	-99,322	'
ASSETS	'	'	'	'	'
Cash and Cash Equivalents, at Carrying Value	0	'	0	'	'
Accounts Receivable, Net, Current	-192	'	-192	'	-210
Inventory, Net	0	'	0	'	0
Deferred Tax Assets, Net of Valuation Allowance, Current	0	'	0	'	0
Other Assets, Current	0	'	0	'	0
Assets of Disposal Group, Including Discontinued Operation, Current	0	'	0	'	0
Total current assets	-192	'	-192	'	-210
Property, Plant and Equipment, Net	0	'	0	'	0
Goodwill	0	'	0	'	0
Intangible Assets, Net (Excluding Goodwill)	0	'	0	'	0
Other Assets, Noncurrent	0	'	0	'	0
Disposal Group, Including Discontinued Operation, Long Lived Assets, Noncurrent	0	'	0	'	0
Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures	-4,952,869	'	-4,952,869	'	-5,131,280
Total assets	-4,953,061	'	-4,953,061	'	-5,131,490
LIABILITIES AND STOCKHOLDERS' EQUITY	'	'	'	'	'
Current liabilities of continuing operations, excluding current portion of long-term debt	-192	'	-192	'	-210
Debt, Current	0	'	0	'	0
Liabilities of Disposal Group, Including Discontinued Operation, Current	0	'	0	'	0
Temporary Equity, Liquidation Preference	0	'	0	'	0
Long-term Debt, Excluding Current Maturities	0	'	0	'	0
Deferred income tax liabilities	0	'	0	'	0
Other noncurrent liabilities	0	'	0	'	0
Stockholders' equity	-4,952,869	'	-4,952,869	'	-5,131,280
Total liabilities and stockholders' equity	-4,953,061	'	-4,953,061	'	-5,131,490
Cash flows from financing activities:	'	'	'	'	'
Cash and cash equivalents at beginning of period	'	'	0	'	'
Cash and cash equivalents at end of period	0	'	0	'	'
Consolidating, Eliminating Adjustments [Member] | Guaranteed Senior Notes Payable [Member]	'	'	'	'	'
Summary Consolidating Statements of Income [Abstract]	'	'	'	'	'
Net sales	0	0	0	0	'
Cost of sales	0	0	0	0	'
Gross profit	0	0	0	0	'
Selling, general and administrative expenses	0	0	0	0	'
Provision for doubtful accounts	0	0	0	0	'
Settlement, litigation and other related charges	0	0	0	0	'
Other miscellaneous charges	0	0	0	0	'
Operating income	0	0	0	0	'
Interest expense, net of investment income	0	0	0	0	'
Income before income taxes	0	0	0	0	'
Income tax (benefit) expense	0	0	0	0	'
Income (Loss) from Continuing Operations Attributable to Parent	0	0	0	0	'
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest	0	0	0	0	'
Equity of net income (loss) of subsidiaries	-82,837	44,412	-205,887	-99,322	'
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	-82,837	44,412	-205,887	-99,322	'
ASSETS	'	'	'	'	'
Cash and Cash Equivalents, at Carrying Value	0	'	0	'	'
Accounts Receivable, Net, Current	-92,326	'	-92,326	'	-313,368
Inventory, Net	0	'	0	'	0
Deferred Tax Assets, Net of Valuation Allowance, Current	-425	'	-425	'	-54
Other Assets, Current	0	'	0	'	0
Assets of Disposal Group, Including Discontinued Operation, Current	0	'	0	'	0
Total current assets	-92,751	'	-92,751	'	-313,422
Property, Plant and Equipment, Net	0	'	0	'	0
Goodwill	0	'	0	'	0
Intangible Assets, Net (Excluding Goodwill)	0	'	0	'	0
Other Assets, Noncurrent	0	'	0	'	0
Disposal Group, Including Discontinued Operation, Long Lived Assets, Noncurrent	0	'	0	'	0
Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures	-4,952,869	'	-4,952,869	'	-5,131,280
Total assets	-5,045,620	'	-5,045,620	'	-5,444,702
LIABILITIES AND STOCKHOLDERS' EQUITY	'	'	'	'	'
Current liabilities of continuing operations, excluding current portion of long-term debt	-92,326	'	-92,326	'	-313,368
Debt, Current	0	'	0	'	0
Liabilities of Disposal Group, Including Discontinued Operation, Current	0	'	0	'	0
Temporary Equity, Liquidation Preference	0	'	0	'	0
Long-term Debt, Excluding Current Maturities	0	'	0	'	0
Deferred income tax liabilities	-425	'	-425	'	-54
Other noncurrent liabilities	0	'	0	'	0
Stockholders' equity	-4,952,869	'	-4,952,869	'	-5,131,280
Total liabilities and stockholders' equity	-5,045,620	'	-5,045,620	'	-5,444,702
Cash flows from financing activities:	'	'	'	'	'
Cash and cash equivalents at beginning of period	'	'	0	'	'
Cash and cash equivalents at end of period	$0	'	$0	'	'